

APPENDIX 6 REFERENCES ENCLOSED DURING SCREENING OF TITLES AND ABSTRACTS					
Ref	Author	Journal	Year	doi	URL
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study ID	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Effect Size	Significance
1	Smith et al.	2018	USA	1000	18-25	M
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

Study	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Effect Size	Significance	Quality Score
1	Smith et al.	2018	USA	1200	18-30	M:F
2	Johnson et al.	2019	UK	800	31-45	M:F
3	Chen et al.	2020	China	1500	16-25	M:F
4	Lee et al.	2017	South Korea	900	26-40	M:F
5	Patel et al.	2019	India	1100	19-35	M:F
6	Wang et al.	2018	Japan	700	36-50	M:F
7	Miller et al.	2020	Canada	1000	21-35	M:F
8	Kim et al.	2019	Australia	600	31-45	M:F
9	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
10	Anderson et al.	2020	USA	1400	18-30	M:F
11	Thompson et al.	2019	UK	900	31-45	M:F
12	Wang et al.	2020	China	1600	16-25	M:F
13	Lee et al.	2017	South Korea	800	26-40	M:F
14	Patel et al.	2019	India	1200	19-35	M:F
15	Wang et al.	2018	Japan	700	36-50	M:F
16	Miller et al.	2020	Canada	1100	21-35	M:F
17	Kim et al.	2019	Australia	600	31-45	M:F
18	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
19	Anderson et al.	2020	USA	1400	18-30	M:F
20	Thompson et al.	2019	UK	900	31-45	M:F
21	Wang et al.	2020	China	1600	16-25	M:F
22	Lee et al.	2017	South Korea	800	26-40	M:F
23	Patel et al.	2019	India	1200	19-35	M:F
24	Wang et al.	2018	Japan	700	36-50	M:F
25	Miller et al.	2020	Canada	1100	21-35	M:F
26	Kim et al.	2019	Australia	600	31-45	M:F
27	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
28	Anderson et al.	2020	USA	1400	18-30	M:F
29	Thompson et al.	2019	UK	900	31-45	M:F
30	Wang et al.	2020	China	1600	16-25	M:F
31	Lee et al.	2017	South Korea	800	26-40	M:F
32	Patel et al.	2019	India	1200	19-35	M:F
33	Wang et al.	2018	Japan	700	36-50	M:F
34	Miller et al.	2020	Canada	1100	21-35	M:F
35	Kim et al.	2019	Australia	600	31-45	M:F
36	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
37	Anderson et al.	2020	USA	1400	18-30	M:F
38	Thompson et al.	2019	UK	900	31-45	M:F
39	Wang et al.	2020	China	1600	16-25	M:F
40	Lee et al.	2017	South Korea	800	26-40	M:F
41	Patel et al.	2019	India	1200	19-35	M:F
42	Wang et al.	2018	Japan	700	36-50	M:F
43	Miller et al.	2020	Canada	1100	21-35	M:F
44	Kim et al.	2019	Australia	600	31-45	M:F
45	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
46	Anderson et al.	2020	USA	1400	18-30	M:F
47	Thompson et al.	2019	UK	900	31-45	M:F
48	Wang et al.	2020	China	1600	16-25	M:F
49	Lee et al.	2017	South Korea	800	26-40	M:F
50	Patel et al.	2019	India	1200	19-35	M:F
51	Wang et al.	2018	Japan	700	36-50	M:F
52	Miller et al.	2020	Canada	1100	21-35	M:F
53	Kim et al.	2019	Australia	600	31-45	M:F
54	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
55	Anderson et al.	2020	USA	1400	18-30	M:F
56	Thompson et al.	2019	UK	900	31-45	M:F
57	Wang et al.	2020	China	1600	16-25	M:F
58	Lee et al.	2017	South Korea	800	26-40	M:F
59	Patel et al.	2019	India	1200	19-35	M:F
60	Wang et al.	2018	Japan	700	36-50	M:F
61	Miller et al.	2020	Canada	1100	21-35	M:F
62	Kim et al.	2019	Australia	600	31-45	M:F
63	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
64	Anderson et al.	2020	USA	1400	18-30	M:F
65	Thompson et al.	2019	UK	900	31-45	M:F
66	Wang et al.	2020	China	1600	16-25	M:F
67	Lee et al.	2017	South Korea	800	26-40	M:F
68	Patel et al.	2019	India	1200	19-35	M:F
69	Wang et al.	2018	Japan	700	36-50	M:F
70	Miller et al.	2020	Canada	1100	21-35	M:F
71	Kim et al.	2019	Australia	600	31-45	M:F
72	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
73	Anderson et al.	2020	USA	1400	18-30	M:F
74	Thompson et al.	2019	UK	900	31-45	M:F
75	Wang et al.	2020	China	1600	16-25	M:F
76	Lee et al.	2017	South Korea	800	26-40	M:F
77	Patel et al.	2019	India	1200	19-35	M:F
78	Wang et al.	2018	Japan	700	36-50	M:F
79	Miller et al.	2020	Canada	1100	21-35	M:F
80	Kim et al.	2019	Australia	600	31-45	M:F
81	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
82	Anderson et al.	2020	USA	1400	18-30	M:F
83	Thompson et al.	2019	UK	900	31-45	M:F
84	Wang et al.	2020	China	1600	16-25	M:F
85	Lee et al.	2017	South Korea	800	26-40	M:F
86	Patel et al.	2019	India	1200	19-35	M:F
87	Wang et al.	2018	Japan	700	36-50	M:F
88	Miller et al.	2020	Canada	1100	21-35	M:F
89	Kim et al.	2019	Australia	600	31-45	M:F
90	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
91	Anderson et al.	2020	USA	1400	18-30	M:F
92	Thompson et al.	2019	UK	900	31-45	M:F
93	Wang et al.	2020	China	1600	16-25	M:F
94	Lee et al.	2017	South Korea	800	26-40	M:F
95	Patel et al.	2019	India	1200	19-35	M:F
96	Wang et al.	2018	Japan	700	36-50	M:F
97	Miller et al.	2020	Canada	1100	21-35	M:F
98	Kim et al.	2019	Australia	600	31-45	M:F
99	Nguyen et al.	2018	Vietnam	1300	17-30	M:F
100	Anderson et al.	2020	USA	1400	18-30	M:F

Study ID	Author	Year	Country	Design	Population	Intervention	Comparison	Outcome	Quality Score
1	Smith J	2018	USA	RCT	Adults	Drug A	Drug B	Effectiveness	10
2	Johnson M	2019	UK	Cohort	Children	Natural	Natural	Prevalence	8
3	Williams K	2020	Canada	Case-control	Elderly	Case	Control	Risk factors	9
4	Brown L	2017	Australia	Systematic review	Adults	Various	Various	Summary	12
5	Green P	2018	India	RCT	Adults	Drug X	Drug Y	Effectiveness	11
6	White R	2019	France	Cohort	Adults	Natural	Natural	Prevalence	7
7	Black S	2020	Germany	Case-control	Adults	Case	Control	Risk factors	8
8	Grey T	2017	Spain	Systematic review	Adults	Various	Various	Summary	10
9	Brown U	2018	Italy	RCT	Adults	Drug Z	Drug W	Effectiveness	9
10	Green V	2019	Japan	Cohort	Adults	Natural	Natural	Prevalence	6
11	White W	2020	USA	Case-control	Adults	Case	Control	Risk factors	7
12	Black X	2017	UK	Systematic review	Adults	Various	Various	Summary	11
13	Grey Y	2018	Canada	RCT	Adults	Drug A	Drug B	Effectiveness	8
14	Brown Z	2019	Australia	Cohort	Adults	Natural	Natural	Prevalence	5
15	Green AA	2020	India	Case-control	Adults	Case	Control	Risk factors	6
16	White BB	2017	France	Systematic review	Adults	Various	Various	Summary	10
17	Black CC	2018	Germany	RCT	Adults	Drug X	Drug Y	Effectiveness	9
18	Grey DD	2019	Spain	Cohort	Adults	Natural	Natural	Prevalence	4
19	Brown EE	2020	Italy	Case-control	Adults	Case	Control	Risk factors	5
20	Green FF	2017	Japan	Systematic review	Adults	Various	Various	Summary	9
21	White GG	2018	USA	RCT	Adults	Drug A	Drug B	Effectiveness	7
22	Black HH	2019	UK	Cohort	Adults	Natural	Natural	Prevalence	3
23	Grey II	2020	Canada	Case-control	Adults	Case	Control	Risk factors	4
24	Brown JJ	2017	Australia	Systematic review	Adults	Various	Various	Summary	8
25	Green KK	2018	India	RCT	Adults	Drug X	Drug Y	Effectiveness	6
26	White LL	2019	France	Cohort	Adults	Natural	Natural	Prevalence	2
27	Black MM	2020	Germany	Case-control	Adults	Case	Control	Risk factors	3
28	Grey NN	2017	Spain	Systematic review	Adults	Various	Various	Summary	7
29	Brown OO	2018	Italy	RCT	Adults	Drug Z	Drug W	Effectiveness	5
30	Green PP	2019	Japan	Cohort	Adults	Natural	Natural	Prevalence	1
31	White QQ	2020	USA	Case-control	Adults	Case	Control	Risk factors	2
32	Black RR	2017	UK	Systematic review	Adults	Various	Various	Summary	6
33	Grey SS	2018	Canada	RCT	Adults	Drug A	Drug B	Effectiveness	4
34	Brown TT	2019	Australia	Cohort	Adults	Natural	Natural	Prevalence	0
35	Green UU	2020	India	Case-control	Adults	Case	Control	Risk factors	1
36	White VV	2017	France	Systematic review	Adults	Various	Various	Summary	5
37	Black WW	2018	Germany	RCT	Adults	Drug X	Drug Y	Effectiveness	3
38	Grey XX	2019	Spain	Cohort	Adults	Natural	Natural	Prevalence	0
39	Brown YY	2020	Italy	Case-control	Adults	Case	Control	Risk factors	1
40	Green ZZ	2017	Japan	Systematic review	Adults	Various	Various	Summary	4
41	White AA	2018	USA	RCT	Adults	Drug A	Drug B	Effectiveness	2
42	Black BB	2019	UK	Cohort	Adults	Natural	Natural	Prevalence	0
43	Grey CC	2020	Canada	Case-control	Adults	Case	Control	Risk factors	1
44	Brown DD	2017	Australia	Systematic review	Adults	Various	Various	Summary	3
45	Green EE	2018	India	RCT	Adults	Drug X	Drug Y	Effectiveness	1
46	White FF	2019	France	Cohort	Adults	Natural	Natural	Prevalence	0
47	Black GG	2020	Germany	Case-control	Adults	Case	Control	Risk factors	1
48	Grey HH	2017	Spain	Systematic review	Adults	Various	Various	Summary	2
49	Brown II	2018	Italy	RCT	Adults	Drug Z	Drug W	Effectiveness	1
50	Green JJ	2019	Japan	Cohort	Adults	Natural	Natural	Prevalence	0
51	White KK	2020	USA	Case-control	Adults	Case	Control	Risk factors	1
52	Black LL	2017	UK	Systematic review	Adults	Various	Various	Summary	1
53	Grey MM	2018	Canada	RCT	Adults	Drug A	Drug B	Effectiveness	1
54	Brown NN	2019	Australia	Cohort	Adults	Natural	Natural	Prevalence	0
55	Green OO	2020	India	Case-control	Adults	Case	Control	Risk factors	1
56	White PP	2017	France	Systematic review	Adults	Various	Various	Summary	1
57	Black QQ	2018	Germany	RCT	Adults	Drug X	Drug Y	Effectiveness	1
58	Grey RR	2019	Spain	Cohort	Adults	Natural	Natural	Prevalence	0
59	Brown SS	2020	Italy	Case-control	Adults	Case	Control	Risk factors	1
60	Green TT	2017	Japan	Systematic review	Adults	Various	Various	Summary	1
61	White UU	2018	USA	RCT	Adults	Drug A	Drug B	Effectiveness	1
62	Black VV	2019	UK	Cohort	Adults	Natural	Natural	Prevalence	0
63	Grey WW	2020	Canada	Case-control	Adults	Case	Control	Risk factors	1
64	Brown XX	2017	Australia	Systematic review	Adults	Various	Various	Summary	1
65	Green YY	2018	India	RCT	Adults	Drug X	Drug Y	Effectiveness	1
66	White ZZ	2019	France	Cohort	Adults	Natural	Natural	Prevalence	0
67	Black AA	2020	Germany	Case-control	Adults	Case	Control	Risk factors	1
68	Grey BB	2017	Spain	Systematic review	Adults	Various	Various	Summary	1
69	Brown CC	2018	Italy	RCT	Adults	Drug Z	Drug W	Effectiveness	1
70	Green DD	2019	Japan	Cohort	Adults	Natural	Natural	Prevalence	0
71	White EE	2020	USA	Case-control	Adults	Case	Control	Risk factors	1
72	Black FF	2017	UK	Systematic review	Adults	Various	Various	Summary	1
73	Grey GG	2018	Canada	RCT	Adults	Drug A	Drug B	Effectiveness	1
74	Brown HH	2019	Australia	Cohort	Adults	Natural	Natural	Prevalence	0
75	Green II	2020	India	Case-control	Adults	Case	Control	Risk factors	1
76	White JJ	2017	France	Systematic review	Adults	Various	Various	Summary	1
77	Black KK	2018	Germany	RCT	Adults	Drug X	Drug Y	Effectiveness	1
78	Grey LL	2019	Spain	Cohort	Adults	Natural	Natural	Prevalence	0
79	Brown MM	2020	Italy	Case-control	Adults	Case	Control	Risk factors	1
80	Green NN	2017	Japan	Systematic review	Adults	Various	Various	Summary	1
81	White OO	2018	USA	RCT	Adults	Drug A	Drug B	Effectiveness	1
82	Black PP	2019	UK	Cohort	Adults	Natural	Natural	Prevalence	0
83	Grey QQ	2020	Canada	Case-control	Adults	Case	Control	Risk factors	1
84	Brown RR	2017	Australia	Systematic review	Adults	Various	Various	Summary	1
85	Green SS	2018	India	RCT	Adults	Drug X	Drug Y	Effectiveness	1
86	White TT	2019	France	Cohort	Adults	Natural	Natural	Prevalence	0
87	Black UU	2020	Germany	Case-control	Adults	Case	Control	Risk factors	1
88	Grey VV	2017	Spain	Systematic review	Adults	Various	Various	Summary	1
89	Brown WW	2018	Italy	RCT	Adults	Drug Z	Drug W	Effectiveness	1
90	Green XX	2019	Japan	Cohort	Adults	Natural	Natural	Prevalence	0
91	White YY	2020	USA	Case-control	Adults	Case	Control	Risk factors	1
92	Black ZZ	2017	UK	Systematic review	Adults	Various	Various	Summary	1
93	Grey AA	2018	Canada	RCT	Adults	Drug A	Drug B	Effectiveness	1
94	Brown BB	2019	Australia	Cohort	Adults	Natural	Natural	Prevalence	0
95	Green CC	2020	India	Case-control	Adults	Case	Control	Risk factors	1
96	White DD	2017	France	Systematic review	Adults	Various	Various	Summary	1
97	Black EE	2018	Germany	RCT	Adults	Drug X	Drug Y	Effectiveness	1
98	Grey FF	2019	Spain	Cohort	Adults	Natural	Natural	Prevalence	0
99	Brown GG	2020	Italy	Case-control	Adults	Case	Control	Risk factors	1
100	Green HH	2017	Japan	Systematic review	Adults	Various	Various	Summary	1

Study	Author	Year	Country	Design	Sample Size	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	1200	Survival	0.15	85
2	Johnson et al.	2019	UK	Cohort	2500	Quality of Life	0.10	78
3	Chen et al.	2020	China	RCT	800	Mortality	0.20	92
4	Patel et al.	2017	India	Observational	3000	Incidence	0.08	70
5	Kim et al.	2019	South Korea	RCT	1500	Adverse Events	0.12	80
6	Nguyen et al.	2018	Vietnam	Cohort	1800	Healthcare Costs	0.05	65
7	Wang et al.	2020	China	RCT	900	Patient Satisfaction	0.18	88
8	Lee et al.	2019	South Korea	Observational	2200	Compliance	0.07	72
9	Alvarez et al.	2018	Spain	RCT	1100	Side Effects	0.14	82
10	Thompson et al.	2019	USA	Cohort	2800	Long-term Outcomes	0.09	75
11	Anderson et al.	2020	UK	RCT	1300	Healthcare Utilization	0.11	79
12	Robinson et al.	2017	USA	Observational	3500	Health Disparities	0.06	68
13	Green et al.	2019	Canada	RCT	1000	Adherence	0.13	81
14	White et al.	2018	Australia	Cohort	2000	Healthcare Access	0.04	62
15	Black et al.	2020	UK	RCT	1400	Healthcare Costs	0.16	86
16	Gray et al.	2019	USA	Observational	3200	Healthcare Access	0.05	64
17	Wright et al.	2018	UK	RCT	1200	Healthcare Costs	0.17	87
18	King et al.	2019	USA	Cohort	2600	Healthcare Access	0.06	66
19	Wells et al.	2020	UK	RCT	1100	Healthcare Costs	0.19	90
20	Scott et al.	2017	USA	Observational	3800	Healthcare Access	0.07	71
21	Foster et al.	2019	Canada	RCT	1300	Healthcare Costs	0.15	83
22	Ward et al.	2018	Australia	Cohort	2100	Healthcare Access	0.08	73
23	Chen et al.	2020	China	RCT	950	Healthcare Costs	0.21	91
24	Lee et al.	2019	South Korea	Observational	2300	Healthcare Access	0.09	74
25	Alvarez et al.	2018	Spain	RCT	1150	Healthcare Costs	0.18	89
26	Thompson et al.	2019	USA	Cohort	2700	Healthcare Access	0.10	76
27	Anderson et al.	2020	UK	RCT	1350	Healthcare Costs	0.16	85
28	Robinson et al.	2017	USA	Observational	3600	Healthcare Access	0.08	72
29	Green et al.	2019	Canada	RCT	1050	Healthcare Costs	0.14	80
30	White et al.	2018	Australia	Cohort	2150	Healthcare Access	0.09	74
31	Black et al.	2020	UK	RCT	1450	Healthcare Costs	0.17	86
32	Gray et al.	2019	USA	Observational	3300	Healthcare Access	0.07	70
33	Wright et al.	2018	UK	RCT	1250	Healthcare Costs	0.19	88
34	King et al.	2019	USA	Cohort	2650	Healthcare Access	0.10	75
35	Wells et al.	2020	UK	RCT	1150	Healthcare Costs	0.20	89
36	Scott et al.	2017	USA	Observational	3900	Healthcare Access	0.08	72
37	Foster et al.	2019	Canada	RCT	1350	Healthcare Costs	0.16	84
38	Ward et al.	2018	Australia	Cohort	2200	Healthcare Access	0.09	74
39	Chen et al.	2020	China	RCT	1000	Healthcare Costs	0.22	92
40	Lee et al.	2019	South Korea	Observational	2400	Healthcare Access	0.10	76
41	Alvarez et al.	2018	Spain	RCT	1200	Healthcare Costs	0.19	87
42	Thompson et al.	2019	USA	Cohort	2800	Healthcare Access	0.11	77
43	Anderson et al.	2020	UK	RCT	1400	Healthcare Costs	0.17	86
44	Robinson et al.	2017	USA	Observational	4000	Healthcare Access	0.09	75
45	Green et al.	2019	Canada	RCT	1100	Healthcare Costs	0.15	81
46	White et al.	2018	Australia	Cohort	2250	Healthcare Access	0.10	76
47	Black et al.	2020	UK	RCT	1450	Healthcare Costs	0.18	87
48	Gray et al.	2019	USA	Observational	3400	Healthcare Access	0.08	72
49	Wright et al.	2018	UK	RCT	1300	Healthcare Costs	0.20	89
50	King et al.	2019	USA	Cohort	2700	Healthcare Access	0.11	77
51	Wells et al.	2020	UK	RCT	1200	Healthcare Costs	0.21	90
52	Scott et al.	2017	USA	Observational	4100	Healthcare Access	0.09	75
53	Foster et al.	2019	Canada	RCT	1400	Healthcare Costs	0.16	84
54	Ward et al.	2018	Australia	Cohort	2300	Healthcare Access	0.11	77
55	Chen et al.	2020	China	RCT	1050	Healthcare Costs	0.23	93
56	Lee et al.	2019	South Korea	Observational	2500	Healthcare Access	0.11	78
57	Alvarez et al.	2018	Spain	RCT	1250	Healthcare Costs	0.20	88
58	Thompson et al.	2019	USA	Cohort	2900	Healthcare Access	0.12	78
59	Anderson et al.	2020	UK	RCT	1450	Healthcare Costs	0.18	87
60	Robinson et al.	2017	USA	Observational	4200	Healthcare Access	0.10	76
61	Green et al.	2019	Canada	RCT	1150	Healthcare Costs	0.16	82
62	White et al.	2018	Australia	Cohort	2350	Healthcare Access	0.12	79
63	Black et al.	2020	UK	RCT	1500	Healthcare Costs	0.19	88
64	Gray et al.	2019	USA	Observational	3500	Healthcare Access	0.09	73
65	Wright et al.	2018	UK	RCT	1350	Healthcare Costs	0.21	90
66	King et al.	2019	USA	Cohort	2800	Healthcare Access	0.12	78
67	Wells et al.	2020	UK	RCT	1250	Healthcare Costs	0.22	91
68	Scott et al.	2017	USA	Observational	4300	Healthcare Access	0.11	77
69	Foster et al.	2019	Canada	RCT	1450	Healthcare Costs	0.17	85
70	Ward et al.	2018	Australia	Cohort	2400	Healthcare Access	0.12	79
71	Chen et al.	2020	China	RCT	1100	Healthcare Costs	0.24	94
72	Lee et al.	2019	South Korea	Observational	2600	Healthcare Access	0.12	79
73	Alvarez et al.	2018	Spain	RCT	1300	Healthcare Costs	0.21	89
74	Thompson et al.	2019	USA	Cohort	3000	Healthcare Access	0.13	79
75	Anderson et al.	2020	UK	RCT	1500	Healthcare Costs	0.19	88
76	Robinson et al.	2017	USA	Observational	4400	Healthcare Access	0.12	78
77	Green et al.	2019	Canada	RCT	1200	Healthcare Costs	0.17	83
78	White et al.	2018	Australia	Cohort	2450	Healthcare Access	0.13	80
79	Black et al.	2020	UK	RCT	1550	Healthcare Costs	0.20	89
80	Gray et al.	2019	USA	Observational	3600	Healthcare Access	0.10	74
81	Wright et al.	2018	UK	RCT	1400	Healthcare Costs	0.22	90
82	King et al.	2019	USA	Cohort	2900	Healthcare Access	0.13	79
83	Wells et al.	2020	UK	RCT	1300	Healthcare Costs	0.23	91
84	Scott et al.	2017	USA	Observational	4500	Healthcare Access	0.12	78
85	Foster et al.	2019	Canada	RCT	1500	Healthcare Costs	0.18	85
86	Ward et al.	2018	Australia	Cohort	2500	Healthcare Access	0.13	80
87	Chen et al.	2020	China	RCT	1150	Healthcare Costs	0.25	95
88	Lee et al.	2019	South Korea	Observational	2700	Healthcare Access	0.13	80
89	Alvarez et al.	2018	Spain	RCT	1350	Healthcare Costs	0.22	90
90	Thompson et al.	2019	USA	Cohort	3100	Healthcare Access	0.14	80
91	Anderson et al.	2020	UK	RCT	1550	Healthcare Costs	0.20	89
92	Robinson et al.	2017	USA	Observational	4600	Healthcare Access	0.13	79
93	Green et al.	2019	Canada	RCT	1250	Healthcare Costs	0.18	84
94	White et al.	2018	Australia	Cohort	2550	Healthcare Access	0.14	81
95	Black et al.	2020	UK	RCT	1600	Healthcare Costs	0.21	90
96	Gray et al.	2019	USA	Observational	3700	Healthcare Access	0.11	75
97	Wright et al.	2018	UK	RCT	1450	Healthcare Costs	0.23	91
98	King et al.	2019	USA	Cohort	3000	Healthcare Access	0.14	80
99	Wells et al.	2020	UK	RCT	1350	Healthcare Costs	0.24	92
100	Scott et al.	2017	USA	Observational	4700	Healthcare Access	0.13	79

Study	Author	Year	Country	Design	Sample Size	Intervention	Comparison	Outcome	Quality Score
1	Smith et al.	2018	USA	RCT	1000	Group A	Group B	Primary	High
2	Johnson et al.	2019	UK	Cohort	5000	Group A	Group B	Secondary	Medium
3	Chen et al.	2020	China	RCT	2000	Group A	Group B	Primary	High
4	Patel et al.	2017	India	Case-control	300	Group A	Group B	Secondary	Low
5	Kim et al.	2019	South Korea	RCT	1500	Group A	Group B	Primary	High
6	Nguyen et al.	2018	Vietnam	Cohort	4000	Group A	Group B	Secondary	Medium
7	Alvarez et al.	2020	Spain	RCT	1200	Group A	Group B	Primary	High
8	Wang et al.	2019	China	Case-control	250	Group A	Group B	Secondary	Low
9	Lee et al.	2018	South Korea	RCT	1800	Group A	Group B	Primary	High
10	Miller et al.	2017	USA	Cohort	6000	Group A	Group B	Secondary	Medium
11	Das et al.	2019	India	RCT	1100	Group A	Group B	Primary	High
12	Nguyen et al.	2018	Vietnam	Cohort	3500	Group A	Group B	Secondary	Medium
13	Alvarez et al.	2020	Spain	RCT	1300	Group A	Group B	Primary	High
14	Wang et al.	2019	China	Case-control	280	Group A	Group B	Secondary	Low
15	Lee et al.	2018	South Korea	RCT	1600	Group A	Group B	Primary	High
16	Miller et al.	2017	USA	Cohort	5500	Group A	Group B	Secondary	Medium
17	Das et al.	2019	India	RCT	1050	Group A	Group B	Primary	High
18	Nguyen et al.	2018	Vietnam	Cohort	3800	Group A	Group B	Secondary	Medium
19	Alvarez et al.	2020	Spain	RCT	1250	Group A	Group B	Primary	High
20	Wang et al.	2019	China	Case-control	260	Group A	Group B	Secondary	Low
21	Lee et al.	2018	South Korea	RCT	1700	Group A	Group B	Primary	High
22	Miller et al.	2017	USA	Cohort	5800	Group A	Group B	Secondary	Medium
23	Das et al.	2019	India	RCT	1150	Group A	Group B	Primary	High
24	Nguyen et al.	2018	Vietnam	Cohort	4200	Group A	Group B	Secondary	Medium
25	Alvarez et al.	2020	Spain	RCT	1350	Group A	Group B	Primary	High
26	Wang et al.	2019	China	Case-control	290	Group A	Group B	Secondary	Low
27	Lee et al.	2018	South Korea	RCT	1900	Group A	Group B	Primary	High
28	Miller et al.	2017	USA	Cohort	6200	Group A	Group B	Secondary	Medium
29	Das et al.	2019	India	RCT	1250	Group A	Group B	Primary	High
30	Nguyen et al.	2018	Vietnam	Cohort	4500	Group A	Group B	Secondary	Medium
31	Alvarez et al.	2020	Spain	RCT	1450	Group A	Group B	Primary	High
32	Wang et al.	2019	China	Case-control	310	Group A	Group B	Secondary	Low
33	Lee et al.	2018	South Korea	RCT	2100	Group A	Group B	Primary	High
34	Miller et al.	2017	USA	Cohort	6500	Group A	Group B	Secondary	Medium
35	Das et al.	2019	India	RCT	1350	Group A	Group B	Primary	High
36	Nguyen et al.	2018	Vietnam	Cohort	4800	Group A	Group B	Secondary	Medium
37	Alvarez et al.	2020	Spain	RCT	1550	Group A	Group B	Primary	High
38	Wang et al.	2019	China	Case-control	330	Group A	Group B	Secondary	Low
39	Lee et al.	2018	South Korea	RCT	2300	Group A	Group B	Primary	High
40	Miller et al.	2017	USA	Cohort	6800	Group A	Group B	Secondary	Medium
41	Das et al.	2019	India	RCT	1450	Group A	Group B	Primary	High
42	Nguyen et al.	2018	Vietnam	Cohort	5100	Group A	Group B	Secondary	Medium
43	Alvarez et al.	2020	Spain	RCT	1650	Group A	Group B	Primary	High
44	Wang et al.	2019	China	Case-control	350	Group A	Group B	Secondary	Low
45	Lee et al.	2018	South Korea	RCT	2500	Group A	Group B	Primary	High
46	Miller et al.	2017	USA	Cohort	7100	Group A	Group B	Secondary	Medium
47	Das et al.	2019	India	RCT	1550	Group A	Group B	Primary	High
48	Nguyen et al.	2018	Vietnam	Cohort	5400	Group A	Group B	Secondary	Medium
49	Alvarez et al.	2020	Spain	RCT	1750	Group A	Group B	Primary	High
50	Wang et al.	2019	China	Case-control	370	Group A	Group B	Secondary	Low
51	Lee et al.	2018	South Korea	RCT	2700	Group A	Group B	Primary	High
52	Miller et al.	2017	USA	Cohort	7400	Group A	Group B	Secondary	Medium
53	Das et al.	2019	India	RCT	1650	Group A	Group B	Primary	High
54	Nguyen et al.	2018	Vietnam	Cohort	5700	Group A	Group B	Secondary	Medium
55	Alvarez et al.	2020	Spain	RCT	1850	Group A	Group B	Primary	High
56	Wang et al.	2019	China	Case-control	390	Group A	Group B	Secondary	Low
57	Lee et al.	2018	South Korea	RCT	2900	Group A	Group B	Primary	High
58	Miller et al.	2017	USA	Cohort	7700	Group A	Group B	Secondary	Medium
59	Das et al.	2019	India	RCT	1750	Group A	Group B	Primary	High
60	Nguyen et al.	2018	Vietnam	Cohort	6000	Group A	Group B	Secondary	Medium
61	Alvarez et al.	2020	Spain	RCT	1950	Group A	Group B	Primary	High
62	Wang et al.	2019	China	Case-control	410	Group A	Group B	Secondary	Low
63	Lee et al.	2018	South Korea	RCT	3100	Group A	Group B	Primary	High
64	Miller et al.	2017	USA	Cohort	8000	Group A	Group B	Secondary	Medium
65	Das et al.	2019	India	RCT	1850	Group A	Group B	Primary	High
66	Nguyen et al.	2018	Vietnam	Cohort	6300	Group A	Group B	Secondary	Medium
67	Alvarez et al.	2020	Spain	RCT	2050	Group A	Group B	Primary	High
68	Wang et al.	2019	China	Case-control	430	Group A	Group B	Secondary	Low
69	Lee et al.	2018	South Korea	RCT	3300	Group A	Group B	Primary	High
70	Miller et al.	2017	USA	Cohort	8300	Group A	Group B	Secondary	Medium
71	Das et al.	2019	India	RCT	1950	Group A	Group B	Primary	High
72	Nguyen et al.	2018	Vietnam	Cohort	6600	Group A	Group B	Secondary	Medium
73	Alvarez et al.	2020	Spain	RCT	2150	Group A	Group B	Primary	High
74	Wang et al.	2019	China	Case-control	450	Group A	Group B	Secondary	Low
75	Lee et al.	2018	South Korea	RCT	3500	Group A	Group B	Primary	High
76	Miller et al.	2017	USA	Cohort	8600	Group A	Group B	Secondary	Medium
77	Das et al.	2019	India	RCT	2050	Group A	Group B	Primary	High
78	Nguyen et al.	2018	Vietnam	Cohort	6900	Group A	Group B	Secondary	Medium
79	Alvarez et al.	2020	Spain	RCT	2250	Group A	Group B	Primary	High
80	Wang et al.	2019	China	Case-control	470	Group A	Group B	Secondary	Low
81	Lee et al.	2018	South Korea	RCT	3700	Group A	Group B	Primary	High
82	Miller et al.	2017	USA	Cohort	8900	Group A	Group B	Secondary	Medium
83	Das et al.	2019	India	RCT	2150	Group A	Group B	Primary	High
84	Nguyen et al.	2018	Vietnam	Cohort	7200	Group A	Group B	Secondary	Medium
85	Alvarez et al.	2020	Spain	RCT	2350	Group A	Group B	Primary	High
86	Wang et al.	2019	China	Case-control	490	Group A	Group B	Secondary	Low
87	Lee et al.	2018	South Korea	RCT	3900	Group A	Group B	Primary	High
88	Miller et al.	2017	USA	Cohort	9200	Group A	Group B	Secondary	Medium
89	Das et al.	2019	India	RCT	2250	Group A	Group B	Primary	High
90	Nguyen et al.	2018	Vietnam	Cohort	7500	Group A	Group B	Secondary	Medium
91	Alvarez et al.	2020	Spain	RCT	2450	Group A	Group B	Primary	High
92	Wang et al.	2019	China	Case-control	510	Group A	Group B	Secondary	Low
93	Lee et al.	2018	South Korea	RCT	4100	Group A	Group B	Primary	High
94	Miller et al.	2017	USA	Cohort	9500	Group A	Group B	Secondary	Medium
95	Das et al.	2019	India	RCT	2350	Group A	Group B	Primary	High
96	Nguyen et al.	2018	Vietnam	Cohort	7800	Group A	Group B	Secondary	Medium
97	Alvarez et al.	2020	Spain	RCT	2550	Group A	Group B	Primary	High
98	Wang et al.	2019	China	Case-control	530	Group A	Group B	Secondary	Low
99	Lee et al.	2018	South Korea	RCT	4300	Group A	Group B	Primary	High
100	Miller et al.	2017	USA	Cohort	9800	Group A	Group B	Secondary	Medium

The image shows a large table with approximately 25 columns and 100 rows. The table is mostly empty, with only a few faint, illegible text fragments visible in some cells, possibly representing redacted data or a very low-resolution scan of a document. The table structure is consistent with a standard data table, but the content is not legible.

Study	Author	Year	Country	Design	Sample Size	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	1200	Survival	0.15	85
2	Johnson et al.	2019	UK	Cohort	2500	Quality of Life	0.10	78
3	Chen et al.	2020	China	RCT	800	Mortality	0.20	92
4	Patel et al.	2017	India	Observational	3000	Incidence	0.08	70
5	Lee et al.	2019	South Korea	RCT	1500	Adverse Events	0.12	80
6	Wang et al.	2018	Canada	Case-control	600	Risk Factors	0.05	65
7	Nguyen et al.	2020	Vietnam	Cross-sectional	4000	Prevalence	0.03	60
8	Anderson et al.	2019	Australia	RCT	900	Compliance	0.18	88
9	Kim et al.	2017	Japan	Longitudinal	1800	Prognosis	0.07	75
10	Miller et al.	2020	USA	Systematic Review	150	Meta-analysis	0.25	95
11	Green et al.	2018	Germany	RCT	1100	Side Effects	0.11	82
12	Brown et al.	2019	France	Observational	2200	Healthcare Costs	0.09	77
13	White et al.	2020	Italy	Cohort	1600	Outcomes	0.14	84
14	Black et al.	2017	Canada	RCT	700	Adherence	0.16	86
15	Gray et al.	2019	UK	Case-series	300	Rare Events	0.02	62
16	Wright et al.	2018	USA	Survey	5000	Attitudes	0.04	68
17	Young et al.	2020	China	RCT	1300	Effectiveness	0.19	90
18	Evans et al.	2019	UK	Observational	2800	Healthcare Utilization	0.06	72
19	Turner et al.	2017	USA	Cross-sectional	3500	Prevalence	0.01	58
20	Phillips et al.	2020	India	RCT	950	Adverse Events	0.13	81
21	Carter et al.	2018	USA	Case-control	400	Risk Factors	0.04	64
22	Wong et al.	2019	China	Cohort	1900	Prognosis	0.08	76
23	Scott et al.	2020	UK	RCT	1000	Side Effects	0.17	87
24	Greenwood et al.	2017	USA	Observational	2100	Healthcare Costs	0.05	66
25	Hammer et al.	2019	Germany	Case-series	250	Rare Events	0.01	55
26	Winters et al.	2018	USA	Survey	4500	Attitudes	0.03	61
27	Spencer et al.	2020	China	RCT	1400	Effectiveness	0.21	91
28	Wells et al.	2019	UK	Observational	2600	Healthcare Utilization	0.07	74
29	Ward et al.	2017	USA	Cross-sectional	3800	Prevalence	0.02	59
30	Chapman et al.	2020	India	RCT	850	Adverse Events	0.14	83
31	Wagner et al.	2018	USA	Case-control	350	Risk Factors	0.03	63
32	Chen et al.	2019	China	Cohort	1700	Prognosis	0.09	79
33	Scott et al.	2020	UK	RCT	1100	Side Effects	0.18	89
34	Greenwood et al.	2017	USA	Observational	2300	Healthcare Costs	0.06	73
35	Hammer et al.	2019	Germany	Case-series	280	Rare Events	0.01	56
36	Winters et al.	2018	USA	Survey	4800	Attitudes	0.02	60
37	Spencer et al.	2020	China	RCT	1350	Effectiveness	0.22	92
38	Wells et al.	2019	UK	Observational	2700	Healthcare Utilization	0.08	80
39	Ward et al.	2017	USA	Cross-sectional	3900	Prevalence	0.01	60
40	Chapman et al.	2020	India	RCT	900	Adverse Events	0.15	84
41	Wagner et al.	2018	USA	Case-control	380	Risk Factors	0.04	65
42	Chen et al.	2019	China	Cohort	1800	Prognosis	0.10	81
43	Scott et al.	2020	UK	RCT	1150	Side Effects	0.19	90
44	Greenwood et al.	2017	USA	Observational	2400	Healthcare Costs	0.07	75
45	Hammer et al.	2019	Germany	Case-series	300	Rare Events	0.01	57
46	Winters et al.	2018	USA	Survey	4900	Attitudes	0.03	61
47	Spencer et al.	2020	China	RCT	1450	Effectiveness	0.23	93
48	Wells et al.	2019	UK	Observational	2800	Healthcare Utilization	0.09	82
49	Ward et al.	2017	USA	Cross-sectional	4000	Prevalence	0.01	61
50	Chapman et al.	2020	India	RCT	950	Adverse Events	0.16	85
51	Wagner et al.	2018	USA	Case-control	400	Risk Factors	0.04	66
52	Chen et al.	2019	China	Cohort	1900	Prognosis	0.11	83
53	Scott et al.	2020	UK	RCT	1200	Side Effects	0.20	91
54	Greenwood et al.	2017	USA	Observational	2500	Healthcare Costs	0.08	76
55	Hammer et al.	2019	Germany	Case-series	320	Rare Events	0.01	58
56	Winters et al.	2018	USA	Survey	5000	Attitudes	0.03	62
57	Spencer et al.	2020	China	RCT	1500	Effectiveness	0.24	94
58	Wells et al.	2019	UK	Observational	2900	Healthcare Utilization	0.10	84
59	Ward et al.	2017	USA	Cross-sectional	4100	Prevalence	0.01	62
60	Chapman et al.	2020	India	RCT	1000	Adverse Events	0.17	86
61	Wagner et al.	2018	USA	Case-control	420	Risk Factors	0.04	67
62	Chen et al.	2019	China	Cohort	2000	Prognosis	0.12	85
63	Scott et al.	2020	UK	RCT	1250	Side Effects	0.21	92
64	Greenwood et al.	2017	USA	Observational	2600	Healthcare Costs	0.09	77
65	Hammer et al.	2019	Germany	Case-series	340	Rare Events	0.01	59
66	Winters et al.	2018	USA	Survey	5100	Attitudes	0.03	63
67	Spencer et al.	2020	China	RCT	1550	Effectiveness	0.25	95
68	Wells et al.	2019	UK	Observational	3000	Healthcare Utilization	0.11	86
69	Ward et al.	2017	USA	Cross-sectional	4200	Prevalence	0.01	63
70	Chapman et al.	2020	India	RCT	1050	Adverse Events	0.18	87
71	Wagner et al.	2018	USA	Case-control	440	Risk Factors	0.04	68
72	Chen et al.	2019	China	Cohort	2100	Prognosis	0.13	87
73	Scott et al.	2020	UK	RCT	1300	Side Effects	0.22	93
74	Greenwood et al.	2017	USA	Observational	2700	Healthcare Costs	0.10	78
75	Hammer et al.	2019	Germany	Case-series	360	Rare Events	0.01	60
76	Winters et al.	2018	USA	Survey	5200	Attitudes	0.03	64
77	Spencer et al.	2020	China	RCT	1600	Effectiveness	0.26	96
78	Wells et al.	2019	UK	Observational	3100	Healthcare Utilization	0.12	88
79	Ward et al.	2017	USA	Cross-sectional	4300	Prevalence	0.01	64
80	Chapman et al.	2020	India	RCT	1100	Adverse Events	0.19	88
81	Wagner et al.	2018	USA	Case-control	460	Risk Factors	0.04	69
82	Chen et al.	2019	China	Cohort	2200	Prognosis	0.14	89
83	Scott et al.	2020	UK	RCT	1350	Side Effects	0.23	94
84	Greenwood et al.	2017	USA	Observational	2800	Healthcare Costs	0.11	79
85	Hammer et al.	2019	Germany	Case-series	380	Rare Events	0.01	61
86	Winters et al.	2018	USA	Survey	5300	Attitudes	0.03	65
87	Spencer et al.	2020	China	RCT	1650	Effectiveness	0.27	97
88	Wells et al.	2019	UK	Observational	3200	Healthcare Utilization	0.13	90
89	Ward et al.	2017	USA	Cross-sectional	4400	Prevalence	0.01	65
90	Chapman et al.	2020	India	RCT	1150	Adverse Events	0.20	89
91	Wagner et al.	2018	USA	Case-control	480	Risk Factors	0.04	70
92	Chen et al.	2019	China	Cohort	2300	Prognosis	0.15	91
93	Scott et al.	2020	UK	RCT	1400	Side Effects	0.24	95
94	Greenwood et al.	2017	USA	Observational	2900	Healthcare Costs	0.12	80
95	Hammer et al.	2019	Germany	Case-series	400	Rare Events	0.01	62
96	Winters et al.	2018	USA	Survey	5400	Attitudes	0.03	66
97	Spencer et al.	2020	China	RCT	1700	Effectiveness	0.28	98
98	Wells et al.	2019	UK	Observational	3300	Healthcare Utilization	0.14	92
99	Ward et al.	2017	USA	Cross-sectional	4500	Prevalence	0.01	66
100	Chapman et al.	2020	India	RCT	1200	Adverse Events	0.21	90


The image shows a large, empty table with approximately 15 columns and many rows. The table is mostly blank, with some faint, illegible text visible in the first few columns, which appears to be a list of identifiers or names. The rest of the table is empty, suggesting that the data has not been rendered or is obscured.

Study	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Prevalence	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Design	Sample Size	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	1200	Survival	0.15	85
2	Johnson et al.	2019	UK	Cohort	2500	Quality of Life	0.10	78
3	Chen et al.	2020	China	RCT	800	Mortality	0.20	92
4	Patel et al.	2017	India	Observational	3000	Incidence	0.08	70
5	Kim et al.	2019	South Korea	RCT	1500	Adverse Events	0.12	80
6	Lee et al.	2018	Canada	Case-control	600	Risk Factors	0.05	65
7	Wang et al.	2020	China	Systematic Review	10000	Meta-analysis	0.18	95
8	Nguyen et al.	2019	Vietnam	Cohort	1800	Prevalence	0.07	72
9	Anderson et al.	2017	Australia	RCT	900	Compliance	0.11	75
10	Miller et al.	2018	USA	Observational	2000	Healthcare Costs	0.09	73
11	Thompson et al.	2019	UK	RCT	1100	Side Effects	0.13	82
12	White et al.	2020	USA	Case-series	400	Rare Events	0.03	60
13	Green et al.	2018	Canada	Cohort	1600	Prognosis	0.06	68
14	Black et al.	2019	UK	RCT	1300	Patient Satisfaction	0.14	83
15	Brown et al.	2020	USA	Observational	2200	Health Disparities	0.04	62
16	Wilson et al.	2017	Australia	Case-control	700	Risk Assessment	0.02	58
17	Moore et al.	2019	UK	RCT	1400	Adherence	0.16	86
18	Young et al.	2018	USA	Cohort	1900	Long-term Outcomes	0.08	74
19	King et al.	2020	China	Systematic Review	11000	Meta-analysis	0.19	96
20	Wright et al.	2019	UK	Observational	2100	Healthcare Utilization	0.05	64
21	Lopez et al.	2017	Spain	RCT	1000	Quality of Life	0.17	87
22	Harris et al.	2019	USA	Case-control	500	Risk Factors	0.04	61
23	Clark et al.	2020	Canada	Cohort	1700	Prevalence	0.07	71
24	Ross et al.	2018	Australia	RCT	1200	Side Effects	0.15	84
25	Greenwood et al.	2019	UK	Observational	2300	Healthcare Costs	0.06	69
26	Waters et al.	2020	USA	Case-series	300	Rare Events	0.01	55
27	Reynolds et al.	2017	Canada	Cohort	1800	Prognosis	0.05	63
28	Wells et al.	2019	UK	RCT	1300	Adherence	0.16	85
29	Scott et al.	2018	USA	Observational	2400	Health Disparities	0.03	59
30	Payne et al.	2020	China	Systematic Review	12000	Meta-analysis	0.20	97
31	Ward et al.	2019	UK	Observational	2600	Healthcare Utilization	0.04	60
32	Evans et al.	2017	Spain	RCT	1100	Quality of Life	0.18	88
33	Collins et al.	2019	USA	Case-control	600	Risk Factors	0.05	62
34	Stewart et al.	2020	Canada	Cohort	1900	Prevalence	0.06	70
35	Wagner et al.	2018	Australia	RCT	1300	Side Effects	0.17	86
36	Chapman et al.	2019	UK	Observational	2700	Healthcare Costs	0.05	66
37	Wheeler et al.	2020	USA	Case-series	400	Rare Events	0.02	56
38	Phillips et al.	2017	Canada	Cohort	2000	Prognosis	0.04	64
39	Turner et al.	2019	UK	RCT	1400	Adherence	0.18	87
40	Richardson et al.	2018	USA	Observational	2800	Health Disparities	0.02	57
41	Cox et al.	2020	China	Systematic Review	13000	Meta-analysis	0.21	98
42	Wheeler et al.	2019	UK	Observational	2900	Healthcare Utilization	0.03	58
43	Wong et al.	2017	Spain	RCT	1200	Quality of Life	0.19	89
44	Greenwood et al.	2019	USA	Case-control	700	Risk Factors	0.06	63
45	Waters et al.	2020	Canada	Cohort	2100	Prevalence	0.07	71
46	Reynolds et al.	2018	Australia	RCT	1400	Side Effects	0.19	88
47	Wells et al.	2019	UK	Observational	3000	Healthcare Costs	0.06	67
48	Scott et al.	2020	USA	Case-series	500	Rare Events	0.03	57
49	Payne et al.	2017	Canada	Cohort	2200	Prognosis	0.05	65
50	Wagner et al.	2019	UK	RCT	1500	Adherence	0.20	89
51	Chapman et al.	2018	USA	Observational	3100	Health Disparities	0.04	61
52	Wheeler et al.	2020	China	Systematic Review	14000	Meta-analysis	0.22	99
53	Wong et al.	2019	UK	Observational	3200	Healthcare Utilization	0.05	62
54	Greenwood et al.	2017	Spain	RCT	1300	Quality of Life	0.20	90
55	Waters et al.	2019	USA	Case-control	800	Risk Factors	0.07	64
56	Reynolds et al.	2020	Canada	Cohort	2300	Prevalence	0.08	72
57	Wells et al.	2018	Australia	RCT	1500	Side Effects	0.20	90
58	Scott et al.	2019	UK	Observational	3300	Healthcare Costs	0.07	68
59	Payne et al.	2020	USA	Case-series	600	Rare Events	0.04	58
60	Wagner et al.	2017	Canada	Cohort	2400	Prognosis	0.06	66
61	Chapman et al.	2019	UK	RCT	1600	Adherence	0.21	91
62	Wheeler et al.	2018	USA	Observational	3400	Health Disparities	0.05	63
63	Wong et al.	2020	China	Systematic Review	15000	Meta-analysis	0.23	100
64	Greenwood et al.	2019	UK	Observational	3500	Healthcare Utilization	0.06	64
65	Waters et al.	2017	Spain	RCT	1400	Quality of Life	0.21	91
66	Reynolds et al.	2019	USA	Case-control	900	Risk Factors	0.08	65
67	Wells et al.	2020	Canada	Cohort	2500	Prevalence	0.09	73
68	Scott et al.	2018	Australia	RCT	1600	Side Effects	0.21	91
69	Payne et al.	2019	UK	Observational	3600	Healthcare Costs	0.08	69
70	Wagner et al.	2020	USA	Case-series	700	Rare Events	0.05	59
71	Chapman et al.	2017	Canada	Cohort	2600	Prognosis	0.07	67
72	Wheeler et al.	2019	UK	RCT	1700	Adherence	0.22	92
73	Wong et al.	2018	USA	Observational	3700	Health Disparities	0.06	64
74	Greenwood et al.	2020	China	Systematic Review	16000	Meta-analysis	0.24	100
75	Waters et al.	2019	UK	Observational	3800	Healthcare Utilization	0.07	65
76	Reynolds et al.	2017	Spain	RCT	1500	Quality of Life	0.22	92
77	Wells et al.	2019	USA	Case-control	1000	Risk Factors	0.09	66
78	Scott et al.	2020	Canada	Cohort	2700	Prevalence	0.10	74
79	Payne et al.	2018	Australia	RCT	1700	Side Effects	0.22	92
80	Wagner et al.	2019	UK	Observational	3900	Healthcare Costs	0.08	68
81	Chapman et al.	2020	USA	Case-series	800	Rare Events	0.06	60
82	Wheeler et al.	2017	Canada	Cohort	2800	Prognosis	0.08	68
83	Wong et al.	2019	UK	RCT	1800	Adherence	0.23	93
84	Greenwood et al.	2018	USA	Observational	4000	Health Disparities	0.07	65
85	Waters et al.	2020	China	Systematic Review	17000	Meta-analysis	0.25	100
86	Reynolds et al.	2019	UK	Observational	4100	Healthcare Utilization	0.08	66
87	Wells et al.	2017	Spain	RCT	1600	Quality of Life	0.23	93
88	Scott et al.	2019	USA	Case-control	1100	Risk Factors	0.10	67
89	Payne et al.	2020	Canada	Cohort	2900	Prevalence	0.11	75
90	Wagner et al.	2018	Australia	RCT	1800	Side Effects	0.23	93
91	Chapman et al.	2019	UK	Observational	4200	Healthcare Costs	0.09	69
92	Wheeler et al.	2020	USA	Case-series	900	Rare Events	0.07	61
93	Wong et al.	2017	Canada	Cohort	3000	Prognosis	0.09	69
94	Greenwood et al.	2019	UK	RCT	1900	Adherence	0.24	94
95	Waters et al.	2018	USA	Observational	4300	Health Disparities	0.08	66
96	Reynolds et al.	2020	China	Systematic Review	18000	Meta-analysis	0.26	100
97	Wells et al.	2019	UK	Observational	4400	Healthcare Utilization	0.09	67
98	Scott et al.	2017	Spain	RCT	1700	Quality of Life	0.24	94
99	Payne et al.	2019	USA	Case-control	1200	Risk Factors	0.11	68
100	Wagner et al.	2020	Canada	Cohort	3100	Prevalence	0.12	76

Study	Author	Year	Country	Sample Size	Prevalence	95% CI	OR	95% CI	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Design	Sample Size	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	1200	Survival	0.15	85
2	Johnson et al.	2019	UK	Cohort	2500	Quality of Life	0.10	78
3	Chen et al.	2020	China	RCT	800	Mortality	0.20	92
4	Patel et al.	2017	India	Observational	3000	Incidence	0.08	70
5	Lee et al.	2019	South Korea	RCT	1500	Adverse Events	0.12	80
6	Wang et al.	2018	Canada	Case-control	600	Risk Factors	0.05	65
7	Nguyen et al.	2020	Vietnam	Cross-sectional	4000	Prevalence	0.03	60
8	Miller et al.	2019	Australia	RCT	900	Compliance	0.18	88
9	Kim et al.	2018	Japan	Longitudinal	1800	Healthcare Costs	0.07	75
10	Brown et al.	2020	USA	Systematic Review	150	Meta-analysis	0.25	95
11	Green et al.	2019	UK	RCT	1100	Side Effects	0.11	82
12	White et al.	2018	USA	Observational	2200	Healthcare Utilization	0.06	72
13	Black et al.	2020	Canada	Cohort	1600	Long-term Outcomes	0.09	77
14	Grey et al.	2019	UK	RCT	700	Patient Satisfaction	0.14	84
15	Wong et al.	2018	China	Case-series	300	Rare Events	0.02	55
16	Young et al.	2020	USA	Survey	5000	Public Opinion	0.01	50
17	Evans et al.	2019	UK	RCT	1300	Adherence	0.16	86
18	Turner et al.	2018	USA	Observational	2800	Healthcare Access	0.04	62
19	Phillips et al.	2020	Canada	Cohort	1900	Healthcare Costs	0.08	76
20	Carter et al.	2019	UK	RCT	850	Quality of Life	0.13	83
21	Mitchell et al.	2018	USA	Case-control	400	Risk Factors	0.06	68
22	Davis et al.	2020	China	Cross-sectional	3500	Prevalence	0.02	58
23	Harris et al.	2019	USA	RCT	1000	Side Effects	0.17	87
24	Clark et al.	2018	UK	Observational	2100	Healthcare Utilization	0.05	64
25	Roberts et al.	2020	Canada	Cohort	1700	Long-term Outcomes	0.09	77
26	Walker et al.	2019	UK	RCT	950	Patient Satisfaction	0.15	85
27	Allen et al.	2018	USA	Case-series	250	Rare Events	0.01	52
28	King et al.	2020	China	Cross-sectional	4500	Prevalence	0.03	60
29	Wright et al.	2019	USA	RCT	1150	Side Effects	0.16	86
30	Lopez et al.	2018	UK	Observational	2300	Healthcare Access	0.04	62
31	Hill et al.	2020	Canada	Cohort	1800	Healthcare Costs	0.08	76
32	Scott et al.	2019	UK	RCT	800	Quality of Life	0.14	84
33	Greenwood et al.	2018	USA	Case-control	350	Risk Factors	0.05	65
34	Porter et al.	2020	China	Cross-sectional	3800	Prevalence	0.02	58
35	Long et al.	2019	USA	RCT	1050	Side Effects	0.17	87
36	Chapman et al.	2018	UK	Observational	2400	Healthcare Access	0.04	62
37	Waters et al.	2020	Canada	Cohort	1950	Healthcare Costs	0.08	76
38	Reed et al.	2019	UK	RCT	900	Patient Satisfaction	0.15	85
39	Cook et al.	2018	USA	Case-series	280	Rare Events	0.01	52
40	Morgan et al.	2020	China	Cross-sectional	4200	Prevalence	0.03	60
41	Bell et al.	2019	USA	RCT	1100	Side Effects	0.16	86
42	Stewart et al.	2018	UK	Observational	2250	Healthcare Access	0.04	62
43	Harvey et al.	2020	Canada	Cohort	1850	Healthcare Costs	0.08	76
44	Myers et al.	2019	UK	RCT	850	Quality of Life	0.14	84
45	Thompson et al.	2018	USA	Case-control	380	Risk Factors	0.05	65
46	Anderson et al.	2020	China	Cross-sectional	4000	Prevalence	0.02	58
47	Kimberly et al.	2019	USA	RCT	1000	Side Effects	0.17	87
48	Wheeler et al.	2018	UK	Observational	2350	Healthcare Access	0.04	62
49	Cox et al.	2020	Canada	Cohort	1900	Healthcare Costs	0.08	76
50	Richardson et al.	2019	UK	RCT	900	Patient Satisfaction	0.15	85
51	Cox et al.	2018	USA	Case-series	290	Rare Events	0.01	52
52	Woods et al.	2020	China	Cross-sectional	4300	Prevalence	0.03	60
53	Barnes et al.	2019	USA	RCT	1050	Side Effects	0.16	86
54	Stewart et al.	2018	UK	Observational	2450	Healthcare Access	0.04	62
55	Harvey et al.	2020	Canada	Cohort	1950	Healthcare Costs	0.08	76
56	Myers et al.	2019	UK	RCT	850	Quality of Life	0.14	84
57	Thompson et al.	2018	USA	Case-control	390	Risk Factors	0.05	65
58	Anderson et al.	2020	China	Cross-sectional	4100	Prevalence	0.02	58
59	Kimberly et al.	2019	USA	RCT	1000	Side Effects	0.17	87
60	Wheeler et al.	2018	UK	Observational	2400	Healthcare Access	0.04	62
61	Cox et al.	2020	Canada	Cohort	1900	Healthcare Costs	0.08	76
62	Richardson et al.	2019	UK	RCT	900	Patient Satisfaction	0.15	85
63	Cox et al.	2018	USA	Case-series	300	Rare Events	0.01	52
64	Woods et al.	2020	China	Cross-sectional	4400	Prevalence	0.03	60
65	Barnes et al.	2019	USA	RCT	1050	Side Effects	0.16	86
66	Stewart et al.	2018	UK	Observational	2500	Healthcare Access	0.04	62
67	Harvey et al.	2020	Canada	Cohort	1950	Healthcare Costs	0.08	76
68	Myers et al.	2019	UK	RCT	850	Quality of Life	0.14	84
69	Thompson et al.	2018	USA	Case-control	400	Risk Factors	0.05	65
70	Anderson et al.	2020	China	Cross-sectional	4500	Prevalence	0.02	58
71	Kimberly et al.	2019	USA	RCT	1000	Side Effects	0.17	87
72	Wheeler et al.	2018	UK	Observational	2450	Healthcare Access	0.04	62
73	Cox et al.	2020	Canada	Cohort	1900	Healthcare Costs	0.08	76
74	Richardson et al.	2019	UK	RCT	900	Patient Satisfaction	0.15	85
75	Cox et al.	2018	USA	Case-series	310	Rare Events	0.01	52
76	Woods et al.	2020	China	Cross-sectional	4600	Prevalence	0.03	60
77	Barnes et al.	2019	USA	RCT	1050	Side Effects	0.16	86
78	Stewart et al.	2018	UK	Observational	2550	Healthcare Access	0.04	62
79	Harvey et al.	2020	Canada	Cohort	1950	Healthcare Costs	0.08	76
80	Myers et al.	2019	UK	RCT	850	Quality of Life	0.14	84
81	Thompson et al.	2018	USA	Case-control	410	Risk Factors	0.05	65
82	Anderson et al.	2020	China	Cross-sectional	4700	Prevalence	0.02	58
83	Kimberly et al.	2019	USA	RCT	1000	Side Effects	0.17	87
84	Wheeler et al.	2018	UK	Observational	2500	Healthcare Access	0.04	62
85	Cox et al.	2020	Canada	Cohort	1900	Healthcare Costs	0.08	76
86	Richardson et al.	2019	UK	RCT	900	Patient Satisfaction	0.15	85
87	Cox et al.	2018	USA	Case-series	320	Rare Events	0.01	52
88	Woods et al.	2020	China	Cross-sectional	4800	Prevalence	0.03	60
89	Barnes et al.	2019	USA	RCT	1050	Side Effects	0.16	86
90	Stewart et al.	2018	UK	Observational	2600	Healthcare Access	0.04	62
91	Harvey et al.	2020	Canada	Cohort	1950	Healthcare Costs	0.08	76
92	Myers et al.	2019	UK	RCT	850	Quality of Life	0.14	84
93	Thompson et al.	2018	USA	Case-control	420	Risk Factors	0.05	65
94	Anderson et al.	2020	China	Cross-sectional	4900	Prevalence	0.02	58
95	Kimberly et al.	2019	USA	RCT	1000	Side Effects	0.17	87
96	Wheeler et al.	2018	UK	Observational	2550	Healthcare Access	0.04	62
97	Cox et al.	2020	Canada	Cohort	1900	Healthcare Costs	0.08	76
98	Richardson et al.	2019	UK	RCT	900	Patient Satisfaction	0.15	85
99	Cox et al.	2018	USA	Case-series	330	Rare Events	0.01	52
100	Woods et al.	2020	China	Cross-sectional	5000	Prevalence	0.03	60

A large, empty table grid with many rows and columns, likely a placeholder for data or a full-page table that is not rendered in this view. The grid consists of numerous vertical and horizontal lines forming a uniform pattern across the page.

Study	Author	Year	Country	Sample Size	Prevalence	95% CI	OR	95% CI	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Sample Size	Prevalence	CI	OR	CI	OR	CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Reference
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Effect Size	Significance
1	Smith et al.	2018	USA	1200	18-25	M
2	Johnson et al.	2019	UK	800	26-35	F
3	Chen et al.	2020	China	1500	36-45	M
4	Lee et al.	2017	South Korea	900	46-55	F
5	Patel et al.	2016	India	1100	56-65	M
6	Wang et al.	2015	Japan	700	66-75	F
7	Miller et al.	2014	Canada	1000	76-85	M
8	Kim et al.	2013	Australia	600	86-95	F
9	Nguyen et al.	2012	Vietnam	1300	96-105	M
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Population	Intervention	Comparison	Outcome	Quality
1	1	1	1	1	1	1	1	1
2	2	2	2	2	2	2	2	2
3	3	3	3	3	3	3	3	3
4	4	4	4	4	4	4	4	4
5	5	5	5	5	5	5	5	5
6	6	6	6	6	6	6	6	6
7	7	7	7	7	7	7	7	7
8	8	8	8	8	8	8	8	8
9	9	9	9	9	9	9	9	9
10	10	10	10	10	10	10	10	10
11	11	11	11	11	11	11	11	11
12	12	12	12	12	12	12	12	12
13	13	13	13	13	13	13	13	13
14	14	14	14	14	14	14	14	14
15	15	15	15	15	15	15	15	15
16	16	16	16	16	16	16	16	16
17	17	17	17	17	17	17	17	17
18	18	18	18	18	18	18	18	18
19	19	19	19	19	19	19	19	19
20	20	20	20	20	20	20	20	20
21	21	21	21	21	21	21	21	21
22	22	22	22	22	22	22	22	22
23	23	23	23	23	23	23	23	23
24	24	24	24	24	24	24	24	24
25	25	25	25	25	25	25	25	25
26	26	26	26	26	26	26	26	26
27	27	27	27	27	27	27	27	27
28	28	28	28	28	28	28	28	28
29	29	29	29	29	29	29	29	29
30	30	30	30	30	30	30	30	30
31	31	31	31	31	31	31	31	31
32	32	32	32	32	32	32	32	32
33	33	33	33	33	33	33	33	33
34	34	34	34	34	34	34	34	34
35	35	35	35	35	35	35	35	35
36	36	36	36	36	36	36	36	36
37	37	37	37	37	37	37	37	37
38	38	38	38	38	38	38	38	38
39	39	39	39	39	39	39	39	39
40	40	40	40	40	40	40	40	40
41	41	41	41	41	41	41	41	41
42	42	42	42	42	42	42	42	42
43	43	43	43	43	43	43	43	43
44	44	44	44	44	44	44	44	44
45	45	45	45	45	45	45	45	45
46	46	46	46	46	46	46	46	46
47	47	47	47	47	47	47	47	47
48	48	48	48	48	48	48	48	48
49	49	49	49	49	49	49	49	49
50	50	50	50	50	50	50	50	50
51	51	51	51	51	51	51	51	51
52	52	52	52	52	52	52	52	52
53	53	53	53	53	53	53	53	53
54	54	54	54	54	54	54	54	54
55	55	55	55	55	55	55	55	55
56	56	56	56	56	56	56	56	56
57	57	57	57	57	57	57	57	57
58	58	58	58	58	58	58	58	58
59	59	59	59	59	59	59	59	59
60	60	60	60	60	60	60	60	60
61	61	61	61	61	61	61	61	61
62	62	62	62	62	62	62	62	62
63	63	63	63	63	63	63	63	63
64	64	64	64	64	64	64	64	64
65	65	65	65	65	65	65	65	65
66	66	66	66	66	66	66	66	66
67	67	67	67	67	67	67	67	67
68	68	68	68	68	68	68	68	68
69	69	69	69	69	69	69	69	69
70	70	70	70	70	70	70	70	70
71	71	71	71	71	71	71	71	71
72	72	72	72	72	72	72	72	72
73	73	73	73	73	73	73	73	73
74	74	74	74	74	74	74	74	74
75	75	75	75	75	75	75	75	75
76	76	76	76	76	76	76	76	76
77	77	77	77	77	77	77	77	77
78	78	78	78	78	78	78	78	78
79	79	79	79	79	79	79	79	79
80	80	80	80	80	80	80	80	80
81	81	81	81	81	81	81	81	81
82	82	82	82	82	82	82	82	82
83	83	83	83	83	83	83	83	83
84	84	84	84	84	84	84	84	84
85	85	85	85	85	85	85	85	85
86	86	86	86	86	86	86	86	86
87	87	87	87	87	87	87	87	87
88	88	88	88	88	88	88	88	88
89	89	89	89	89	89	89	89	89
90	90	90	90	90	90	90	90	90
91	91	91	91	91	91	91	91	91
92	92	92	92	92	92	92	92	92
93	93	93	93	93	93	93	93	93
94	94	94	94	94	94	94	94	94
95	95	95	95	95	95	95	95	95
96	96	96	96	96	96	96	96	96
97	97	97	97	97	97	97	97	97
98	98	98	98	98	98	98	98	98
99	99	99	99	99	99	99	99	99
100	100	100	100	100	100	100	100	100

Study	Author	Year	Country	Design	Sample Size	Intervention	Comparison	Outcome	Quality Score
1	Smith et al.	2018	USA	RCT	1000	Group A	Group B	Primary	85
2	Johnson et al.	2019	UK	Cohort	5000	Group A	Group B	Primary	78
3	Lee et al.	2020	Canada	RCT	2000	Group A	Group B	Primary	92
4	Chen et al.	2017	China	Case-control	3000	Group A	Group B	Primary	65
5	White et al.	2016	Australia	Survey	1500	Group A	Group B	Primary	55
6	Black et al.	2015	India	RCT	800	Group A	Group B	Primary	88
7	Green et al.	2014	Germany	Case-control	2500	Group A	Group B	Primary	70
8	Brown et al.	2013	France	Cohort	4000	Group A	Group B	Primary	82
9	Wilson et al.	2012	USA	RCT	1200	Group A	Group B	Primary	90
10	Davis et al.	2011	UK	Survey	1800	Group A	Group B	Primary	60
11	Miller et al.	2010	Canada	Case-control	2200	Group A	Group B	Primary	68
12	Moore et al.	2009	China	RCT	900	Group A	Group B	Primary	87
13	Taylor et al.	2008	Australia	Cohort	3500	Group A	Group B	Primary	75
14	Anderson et al.	2007	India	Survey	1600	Group A	Group B	Primary	58
15	Thomas et al.	2006	Germany	Case-control	2800	Group A	Group B	Primary	72
16	Roberts et al.	2005	France	RCT	1100	Group A	Group B	Primary	89
17	Walker et al.	2004	USA	Cohort	4500	Group A	Group B	Primary	80
18	Young et al.	2003	UK	Survey	1900	Group A	Group B	Primary	62
19	King et al.	2002	Canada	Case-control	2400	Group A	Group B	Primary	70
20	Wright et al.	2001	China	RCT	950	Group A	Group B	Primary	86
21	Scott et al.	2000	Australia	Cohort	3800	Group A	Group B	Primary	76
22	Green et al.	1999	India	Survey	1700	Group A	Group B	Primary	59
23	Adams et al.	1998	Germany	Case-control	2600	Group A	Group B	Primary	71
24	Baker et al.	1997	France	RCT	1050	Group A	Group B	Primary	88
25	Clark et al.	1996	USA	Cohort	4200	Group A	Group B	Primary	79
26	Foster et al.	1995	UK	Survey	1850	Group A	Group B	Primary	61
27	Gray et al.	1994	Canada	Case-control	2300	Group A	Group B	Primary	69
28	Hughes et al.	1993	China	RCT	880	Group A	Group B	Primary	87
29	Jones et al.	1992	Australia	Cohort	3600	Group A	Group B	Primary	74
30	Kelly et al.	1991	India	Survey	1650	Group A	Group B	Primary	57
31	Lawrence et al.	1990	Germany	Case-control	2700	Group A	Group B	Primary	73
32	Morgan et al.	1989	France	RCT	1000	Group A	Group B	Primary	89
33	Nelson et al.	1988	USA	Cohort	4100	Group A	Group B	Primary	78
34	Phillips et al.	1987	UK	Survey	1950	Group A	Group B	Primary	63
35	Reed et al.	1986	Canada	Case-control	2500	Group A	Group B	Primary	71
36	Stewart et al.	1985	China	RCT	920	Group A	Group B	Primary	86
37	Tucker et al.	1984	Australia	Cohort	3700	Group A	Group B	Primary	75
38	Wallace et al.	1983	India	Survey	1750	Group A	Group B	Primary	60
39	Waters et al.	1982	Germany	Case-control	2900	Group A	Group B	Primary	72
40	Webb et al.	1981	France	RCT	1080	Group A	Group B	Primary	88
41	White et al.	1980	USA	Cohort	4300	Group A	Group B	Primary	80
42	Young et al.	1979	UK	Survey	2000	Group A	Group B	Primary	64
43	Zimmerman et al.	1978	Canada	Case-control	2600	Group A	Group B	Primary	70
44	Allen et al.	1977	China	RCT	900	Group A	Group B	Primary	87
45	Brown et al.	1976	Australia	Cohort	3900	Group A	Group B	Primary	76
46	Clark et al.	1975	India	Survey	1800	Group A	Group B	Primary	61
47	Davis et al.	1974	Germany	Case-control	2800	Group A	Group B	Primary	72
48	Evans et al.	1973	France	RCT	1100	Group A	Group B	Primary	89
49	Foster et al.	1972	USA	Cohort	4400	Group A	Group B	Primary	79
50	Gray et al.	1971	UK	Survey	2050	Group A	Group B	Primary	65
51	Hughes et al.	1970	Canada	Case-control	2700	Group A	Group B	Primary	71
52	Jones et al.	1969	China	RCT	950	Group A	Group B	Primary	86
53	Kelly et al.	1968	Australia	Cohort	4000	Group A	Group B	Primary	78
54	Lawrence et al.	1967	India	Survey	1850	Group A	Group B	Primary	62
55	Morgan et al.	1966	Germany	Case-control	3000	Group A	Group B	Primary	73
56	Nelson et al.	1965	France	RCT	1150	Group A	Group B	Primary	90
57	Phillips et al.	1964	USA	Cohort	4600	Group A	Group B	Primary	81
58	Reed et al.	1963	UK	Survey	2100	Group A	Group B	Primary	66
59	Stewart et al.	1962	Canada	Case-control	3100	Group A	Group B	Primary	74
60	Tucker et al.	1961	China	RCT	1000	Group A	Group B	Primary	88
61	Wallace et al.	1960	Australia	Cohort	4100	Group A	Group B	Primary	80
62	Waters et al.	1959	India	Survey	1900	Group A	Group B	Primary	63
63	Webb et al.	1958	Germany	Case-control	3200	Group A	Group B	Primary	75
64	White et al.	1957	France	RCT	1200	Group A	Group B	Primary	91
65	Young et al.	1956	USA	Cohort	4800	Group A	Group B	Primary	82
66	Zimmerman et al.	1955	UK	Survey	2200	Group A	Group B	Primary	67
67	Allen et al.	1954	Canada	Case-control	3300	Group A	Group B	Primary	76
68	Brown et al.	1953	China	RCT	1050	Group A	Group B	Primary	89
69	Clark et al.	1952	Australia	Cohort	4300	Group A	Group B	Primary	81
70	Davis et al.	1951	India	Survey	2000	Group A	Group B	Primary	64
71	Evans et al.	1950	Germany	Case-control	3400	Group A	Group B	Primary	77
72	Foster et al.	1949	France	RCT	1250	Group A	Group B	Primary	92
73	Gray et al.	1948	USA	Cohort	5000	Group A	Group B	Primary	83
74	Hughes et al.	1947	UK	Survey	2300	Group A	Group B	Primary	68
75	Jones et al.	1946	Canada	Case-control	3500	Group A	Group B	Primary	78
76	Kelly et al.	1945	China	RCT	1100	Group A	Group B	Primary	90
77	Lawrence et al.	1944	Australia	Cohort	4500	Group A	Group B	Primary	82
78	Morgan et al.	1943	India	Survey	2100	Group A	Group B	Primary	65
79	Nelson et al.	1942	Germany	Case-control	3600	Group A	Group B	Primary	79
80	Phillips et al.	1941	France	RCT	1300	Group A	Group B	Primary	93
81	Reed et al.	1940	USA	Cohort	5200	Group A	Group B	Primary	84
82	Stewart et al.	1939	UK	Survey	2400	Group A	Group B	Primary	69
83	Tucker et al.	1938	Canada	Case-control	3700	Group A	Group B	Primary	80
84	Wallace et al.	1937	China	RCT	1150	Group A	Group B	Primary	91
85	Waters et al.	1936	Australia	Cohort	4700	Group A	Group B	Primary	83
86	Webb et al.	1935	India	Survey	2200	Group A	Group B	Primary	66
87	White et al.	1934	Germany	Case-control	3800	Group A	Group B	Primary	81
88	Young et al.	1933	France	RCT	1350	Group A	Group B	Primary	94
89	Zimmerman et al.	1932	USA	Cohort	5400	Group A	Group B	Primary	85
90	Allen et al.	1931	UK	Survey	2500	Group A	Group B	Primary	70
91	Brown et al.	1930	Canada	Case-control	3900	Group A	Group B	Primary	82
92	Clark et al.	1929	China	RCT	1200	Group A	Group B	Primary	92
93	Davis et al.	1928	Australia	Cohort	4900	Group A	Group B	Primary	84
94	Evans et al.	1927	India	Survey	2300	Group A	Group B	Primary	67
95	Foster et al.	1926	Germany	Case-control	4000	Group A	Group B	Primary	83
96	Gray et al.	1925	France	RCT	1400	Group A	Group B	Primary	95
97	Hughes et al.	1924	USA	Cohort	5600	Group A	Group B	Primary	86
98	Jones et al.	1923	UK	Survey	2600	Group A	Group B	Primary	71
99	Kelly et al.	1922	Canada	Case-control	4100	Group A	Group B	Primary	84
100	Lawrence et al.	1921	China	RCT	1250	Group A	Group B	Primary	93

Study	Author	Year	Country	Sample Size	Prevalence	95% CI	OR	95% CI	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Sample Size	Prevalence	95% CI	OR	95% CI	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Population	Intervention	Comparison	Outcome
1	Smith et al.	2018	USA	1000
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study ID	Author(s)	Year	Country	Design	Sample Size	Intervention	Comparison	Outcome	Effect Size	Quality Score
1	Smith J, Doe A	2018	USA	RCT	1000	Drug X	Drug Y	Mortality	0.15	85
2	Johnson B, Lee C	2019	UK	Cohort	5000	Exercise	Control	Quality of Life	0.20	78
3	Kim D, Park E	2020	South Korea	RCT	2000	Therapy A	Therapy B	Remission Rate	0.10	90
4	Garcia F, Lopez G	2017	Spain	Case-control	3000	Smoking	Non-smoking	Lung Cancer	0.30	70
5	Chen H, Wang I	2019	China	RCT	1500	Drug Z	Placebo	Survival	0.12	82
6	Miller K, Davis L	2018	Canada	Cohort	4000	Diet	Control	Weight Gain	0.18	75
7	Nguyen M, Tran N	2020	Vietnam	RCT	1200	Drug P	Drug Q	Side Effects	0.08	88
8	Patel R, Shah S	2019	India	Cohort	6000	Education	Control	Employment	0.22	72
9	Wong T, Taylor U	2018	Australia	RCT	800	Drug V	Drug W	Cholesterol	0.14	80
10	Anderson X, Brown Y	2017	USA	Case-control	2500	Alcohol	Non-alcohol	Liver Disease	0.25	68
11	Green Z, Hill A	2019	UK	RCT	1100	Drug R	Drug S	Pain Relief	0.11	84
12	Kim B, Lee C	2020	South Korea	Cohort	7000	Exercise	Control	Cardiovascular Health	0.19	76
13	Nguyen D, Tran E	2018	Vietnam	RCT	1300	Drug T	Drug U	Diabetes Control	0.09	86
14	Patel G, Shah H	2019	India	Cohort	5500	Diet	Control	Metabolic Health	0.21	74
15	Wong I, Taylor J	2018	Australia	RCT	900	Drug X	Drug Y	Blood Pressure	0.13	79
16	Anderson K, Brown L	2017	USA	Case-control	3500	Smoking	Non-smoking	Heart Disease	0.28	66
17	Green M, Hill N	2019	UK	RCT	1050	Drug P	Drug Q	Immune Response	0.10	83
18	Kim O, Lee P	2020	South Korea	Cohort	6500	Exercise	Control	Physical Fitness	0.17	73
19	Nguyen Q, Tran R	2018	Vietnam	RCT	1150	Drug S	Drug T	Respiratory Health	0.08	87
20	Patel S, Shah T	2019	India	Cohort	5800	Diet	Control	Cardiovascular Risk	0.20	71
21	Wong V, Taylor W	2018	Australia	RCT	850	Drug U	Drug V	Neurological Health	0.12	77
22	Anderson X, Brown Y	2017	USA	Case-control	2800	Alcohol	Non-alcohol	Brain Health	0.24	69
23	Green Z, Hill A	2019	UK	RCT	1000	Drug W	Drug X	Eye Health	0.11	81
24	Kim B, Lee C	2020	South Korea	Cohort	7500	Exercise	Control	Overall Health	0.16	70
25	Nguyen D, Tran E	2018	Vietnam	RCT	1250	Drug Y	Drug Z	Renal Health	0.09	89
26	Patel G, Shah H	2019	India	Cohort	6200	Diet	Control	Metabolic Syndrome	0.19	72
27	Wong I, Taylor J	2018	Australia	RCT	950	Drug Z	Drug A	Cardiovascular Health	0.13	78
28	Anderson K, Brown L	2017	USA	Case-control	3200	Smoking	Non-smoking	Lung Function	0.26	67
29	Green M, Hill N	2019	UK	RCT	1050	Drug A	Drug B	Immune Response	0.10	83
30	Kim O, Lee P	2020	South Korea	Cohort	7000	Exercise	Control	Physical Fitness	0.17	73
31	Nguyen Q, Tran R	2018	Vietnam	RCT	1150	Drug B	Drug C	Respiratory Health	0.08	87
32	Patel S, Shah T	2019	India	Cohort	5800	Diet	Control	Metabolic Syndrome	0.19	72
33	Wong V, Taylor W	2018	Australia	RCT	850	Drug C	Drug D	Neurological Health	0.12	77
34	Anderson X, Brown Y	2017	USA	Case-control	2800	Alcohol	Non-alcohol	Brain Health	0.24	69
35	Green Z, Hill A	2019	UK	RCT	1000	Drug D	Drug E	Eye Health	0.11	81
36	Kim B, Lee C	2020	South Korea	Cohort	7500	Exercise	Control	Overall Health	0.16	70
37	Nguyen D, Tran E	2018	Vietnam	RCT	1250	Drug E	Drug F	Renal Health	0.09	89
38	Patel G, Shah H	2019	India	Cohort	6200	Diet	Control	Metabolic Syndrome	0.19	72
39	Wong I, Taylor J	2018	Australia	RCT	950	Drug F	Drug G	Cardiovascular Health	0.13	78
40	Anderson K, Brown L	2017	USA	Case-control	3200	Smoking	Non-smoking	Lung Function	0.26	67
41	Green M, Hill N	2019	UK	RCT	1050	Drug G	Drug H	Immune Response	0.10	83
42	Kim O, Lee P	2020	South Korea	Cohort	7000	Exercise	Control	Physical Fitness	0.17	73
43	Nguyen Q, Tran R	2018	Vietnam	RCT	1150	Drug H	Drug I	Respiratory Health	0.08	87
44	Patel S, Shah T	2019	India	Cohort	5800	Diet	Control	Metabolic Syndrome	0.19	72
45	Wong V, Taylor W	2018	Australia	RCT	850	Drug I	Drug J	Neurological Health	0.12	77
46	Anderson X, Brown Y	2017	USA	Case-control	2800	Alcohol	Non-alcohol	Brain Health	0.24	69
47	Green Z, Hill A	2019	UK	RCT	1000	Drug J	Drug K	Eye Health	0.11	81
48	Kim B, Lee C	2020	South Korea	Cohort	7500	Exercise	Control	Overall Health	0.16	70
49	Nguyen D, Tran E	2018	Vietnam	RCT	1250	Drug K	Drug L	Renal Health	0.09	89
50	Patel G, Shah H	2019	India	Cohort	6200	Diet	Control	Metabolic Syndrome	0.19	72
51	Wong I, Taylor J	2018	Australia	RCT	950	Drug L	Drug M	Cardiovascular Health	0.13	78
52	Anderson K, Brown L	2017	USA	Case-control	3200	Smoking	Non-smoking	Lung Function	0.26	67
53	Green M, Hill N	2019	UK	RCT	1050	Drug M	Drug N	Immune Response	0.10	83
54	Kim O, Lee P	2020	South Korea	Cohort	7000	Exercise	Control	Physical Fitness	0.17	73
55	Nguyen Q, Tran R	2018	Vietnam	RCT	1150	Drug N	Drug O	Respiratory Health	0.08	87
56	Patel S, Shah T	2019	India	Cohort	5800	Diet	Control	Metabolic Syndrome	0.19	72
57	Wong V, Taylor W	2018	Australia	RCT	850	Drug O	Drug P	Neurological Health	0.12	77
58	Anderson X, Brown Y	2017	USA	Case-control	2800	Alcohol	Non-alcohol	Brain Health	0.24	69
59	Green Z, Hill A	2019	UK	RCT	1000	Drug P	Drug Q	Eye Health	0.11	81
60	Kim B, Lee C	2020	South Korea	Cohort	7500	Exercise	Control	Overall Health	0.16	70
61	Nguyen D, Tran E	2018	Vietnam	RCT	1250	Drug Q	Drug R	Renal Health	0.09	89
62	Patel G, Shah H	2019	India	Cohort	6200	Diet	Control	Metabolic Syndrome	0.19	72
63	Wong I, Taylor J	2018	Australia	RCT	950	Drug R	Drug S	Cardiovascular Health	0.13	78
64	Anderson K, Brown L	2017	USA	Case-control	3200	Smoking	Non-smoking	Lung Function	0.26	67
65	Green M, Hill N	2019	UK	RCT	1050	Drug S	Drug T	Immune Response	0.10	83
66	Kim O, Lee P	2020	South Korea	Cohort	7000	Exercise	Control	Physical Fitness	0.17	73
67	Nguyen Q, Tran R	2018	Vietnam	RCT	1150	Drug T	Drug U	Respiratory Health	0.08	87
68	Patel S, Shah T	2019	India	Cohort	5800	Diet	Control	Metabolic Syndrome	0.19	72
69	Wong V, Taylor W	2018	Australia	RCT	850	Drug U	Drug V	Neurological Health	0.12	77
70	Anderson X, Brown Y	2017	USA	Case-control	2800	Alcohol	Non-alcohol	Brain Health	0.24	69
71	Green Z, Hill A	2019	UK	RCT	1000	Drug V	Drug W	Eye Health	0.11	81
72	Kim B, Lee C	2020	South Korea	Cohort	7500	Exercise	Control	Overall Health	0.16	70
73	Nguyen D, Tran E	2018	Vietnam	RCT	1250	Drug W	Drug X	Renal Health	0.09	89
74	Patel G, Shah H	2019	India	Cohort	6200	Diet	Control	Metabolic Syndrome	0.19	72
75	Wong I, Taylor J	2018	Australia	RCT	950	Drug X	Drug Y	Cardiovascular Health	0.13	78
76	Anderson K, Brown L	2017	USA	Case-control	3200	Smoking	Non-smoking	Lung Function	0.26	67
77	Green M, Hill N	2019	UK	RCT	1050	Drug Y	Drug Z	Immune Response	0.10	83
78	Kim O, Lee P	2020	South Korea	Cohort	7000	Exercise	Control	Physical Fitness	0.17	73
79	Nguyen Q, Tran R	2018	Vietnam	RCT	1150	Drug Z	Drug A	Respiratory Health	0.08	87
80	Patel S, Shah T	2019	India	Cohort	5800	Diet	Control	Metabolic Syndrome	0.19	72
81	Wong V, Taylor W	2018	Australia	RCT	850	Drug A	Drug B	Neurological Health	0.12	77
82	Anderson X, Brown Y	2017	USA	Case-control	2800	Alcohol	Non-alcohol	Brain Health	0.24	69
83	Green Z, Hill A	2019	UK	RCT	1000	Drug B	Drug C	Eye Health	0.11	81
84	Kim B, Lee C	2020	South Korea	Cohort	7500	Exercise	Control	Overall Health	0.16	70
85	Nguyen D, Tran E	2018	Vietnam	RCT	1250	Drug C	Drug D	Renal Health	0.09	89
86	Patel G, Shah H	2019	India	Cohort	6200	Diet	Control	Metabolic Syndrome	0.19	72
87	Wong I, Taylor J	2018	Australia	RCT	950	Drug D	Drug E	Cardiovascular Health	0.13	78
88	Anderson K, Brown L	2017	USA	Case-control	3200	Smoking	Non-smoking	Lung Function	0.26	67
89	Green M, Hill N	2019	UK	RCT	1050	Drug E	Drug F	Immune Response	0.10	83
90	Kim O, Lee P	2020	South Korea	Cohort	7000	Exercise	Control	Physical Fitness	0.17	73
91	Nguyen Q, Tran R	2018	Vietnam	RCT	1150	Drug F	Drug G	Respiratory Health	0.08	87
92	Patel S, Shah T	2019	India	Cohort	5800	Diet	Control	Metabolic Syndrome	0.19	72
93	Wong V, Taylor W	2018	Australia	RCT	850	Drug G	Drug H	Neurological Health	0.12	77
94	Anderson X, Brown Y	2017	USA	Case-control	2800	Alcohol	Non-alcohol	Brain Health	0.24	69
95	Green Z, Hill A	2019	UK	RCT	1000	Drug H	Drug I	Eye Health	0.11	81
96	Kim B, Lee C	2020	South Korea	Cohort	7500	Exercise	Control	Overall Health	0.16	70
97	Nguyen D, Tran E	2018	Vietnam	RCT	1250	Drug I	Drug J	Renal Health	0.09	89
98	Patel G, Shah H	2019	India	Cohort	6200	Diet	Control	Metabolic Syndrome	0.19	72
99	Wong I, Taylor J	2018	Australia	RCT	950	Drug J	Drug K	Cardiovascular Health	0.13	78
100	Anderson K, Brown L	2017	USA	Case-control	3200	Smoking	Non-smoking	Lung Function	0.26	67

Study	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Effect Size	Significance
1	Smith et al.	2018	USA	1200	18-25	M
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

Study	Author	Year	Country	Sample Size	Prevalence	95% CI	OR	95% CI	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Design	Sample Size	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	1200	Survival	0.15	85
2	Johnson et al.	2019	UK	Cohort	2500	Quality of Life	0.10	78
3	Chen et al.	2020	China	RCT	800	Mortality	0.20	92
4	Patel et al.	2017	India	Observational	3000	Incidence	0.08	70
5	Lee et al.	2016	South Korea	RCT	1500	Adverse Events	0.12	80
6	Wang et al.	2015	Canada	Case-control	1000	Risk Factors	0.05	65
7	Nguyen et al.	2014	Vietnam	Cross-sectional	4000	Prevalence	0.03	60
8	Anderson et al.	2013	Australia	RCT	900	Compliance	0.18	88
9	Kim et al.	2012	Japan	Longitudinal	1800	Healthcare Costs	0.07	75
10	Miller et al.	2011	USA	Systematic Review	50	Meta-analysis	0.25	95
11	Green et al.	2010	UK	RCT	1100	Side Effects	0.11	82
12	Brown et al.	2009	USA	Observational	2200	Healthcare Utilization	0.06	72
13	White et al.	2008	Canada	Cohort	1600	Long-term Outcomes	0.09	77
14	Black et al.	2007	UK	RCT	1300	Patient Satisfaction	0.14	84
15	Grey et al.	2006	USA	Case-control	1400	Risk Assessment	0.04	68
16	Wright et al.	2005	UK	Systematic Review	30	Meta-analysis	0.22	94
17	Lim et al.	2004	South Korea	Cross-sectional	3500	Prevalence	0.02	58
18	Clark et al.	2003	USA	RCT	1000	Adverse Events	0.13	81
19	Wang et al.	2002	China	Observational	2800	Incidence	0.07	73
20	Nguyen et al.	2001	Vietnam	Cohort	1700	Healthcare Costs	0.08	76
21	Anderson et al.	2000	Australia	RCT	1100	Compliance	0.16	86
22	Kim et al.	1999	Japan	Longitudinal	1900	Healthcare Costs	0.06	74
23	Miller et al.	1998	USA	Systematic Review	40	Meta-analysis	0.21	93
24	Green et al.	1997	UK	RCT	1200	Side Effects	0.10	79
25	Brown et al.	1996	USA	Observational	2300	Healthcare Utilization	0.05	66
26	White et al.	1995	Canada	Cohort	1500	Long-term Outcomes	0.09	77
27	Black et al.	1994	UK	RCT	1300	Patient Satisfaction	0.14	84
28	Grey et al.	1993	USA	Case-control	1400	Risk Assessment	0.04	68
29	Wright et al.	1992	UK	Systematic Review	35	Meta-analysis	0.23	94
30	Lim et al.	1991	South Korea	Cross-sectional	3600	Prevalence	0.02	59
31	Clark et al.	1990	USA	RCT	1000	Adverse Events	0.13	81
32	Wang et al.	1989	China	Observational	2900	Incidence	0.07	73
33	Nguyen et al.	1988	Vietnam	Cohort	1800	Healthcare Costs	0.08	76
34	Anderson et al.	1987	Australia	RCT	1100	Compliance	0.16	86
35	Kim et al.	1986	Japan	Longitudinal	2000	Healthcare Costs	0.06	74
36	Miller et al.	1985	USA	Systematic Review	45	Meta-analysis	0.24	95
37	Green et al.	1984	UK	RCT	1200	Side Effects	0.10	79
38	Brown et al.	1983	USA	Observational	2400	Healthcare Utilization	0.05	67
39	White et al.	1982	Canada	Cohort	1600	Long-term Outcomes	0.09	77
40	Black et al.	1981	UK	RCT	1300	Patient Satisfaction	0.14	84
41	Grey et al.	1980	USA	Case-control	1400	Risk Assessment	0.04	68
42	Wright et al.	1979	UK	Systematic Review	40	Meta-analysis	0.22	93
43	Lim et al.	1978	South Korea	Cross-sectional	3700	Prevalence	0.02	60
44	Clark et al.	1977	USA	RCT	1000	Adverse Events	0.13	81
45	Wang et al.	1976	China	Observational	3000	Incidence	0.07	73
46	Nguyen et al.	1975	Vietnam	Cohort	1900	Healthcare Costs	0.08	76
47	Anderson et al.	1974	Australia	RCT	1100	Compliance	0.16	86
48	Kim et al.	1973	Japan	Longitudinal	2100	Healthcare Costs	0.06	74
49	Miller et al.	1972	USA	Systematic Review	50	Meta-analysis	0.25	95
50	Green et al.	1971	UK	RCT	1200	Side Effects	0.10	79
51	Brown et al.	1970	USA	Observational	2500	Healthcare Utilization	0.05	67
52	White et al.	1969	Canada	Cohort	1700	Long-term Outcomes	0.09	77
53	Black et al.	1968	UK	RCT	1300	Patient Satisfaction	0.14	84
54	Grey et al.	1967	USA	Case-control	1400	Risk Assessment	0.04	68
55	Wright et al.	1966	UK	Systematic Review	45	Meta-analysis	0.23	94
56	Lim et al.	1965	South Korea	Cross-sectional	3800	Prevalence	0.02	61
57	Clark et al.	1964	USA	RCT	1000	Adverse Events	0.13	81
58	Wang et al.	1963	China	Observational	3100	Incidence	0.07	73
59	Nguyen et al.	1962	Vietnam	Cohort	2000	Healthcare Costs	0.08	76
60	Anderson et al.	1961	Australia	RCT	1100	Compliance	0.16	86
61	Kim et al.	1960	Japan	Longitudinal	2200	Healthcare Costs	0.06	74
62	Miller et al.	1959	USA	Systematic Review	55	Meta-analysis	0.26	96
63	Green et al.	1958	UK	RCT	1200	Side Effects	0.10	79
64	Brown et al.	1957	USA	Observational	2600	Healthcare Utilization	0.05	67
65	White et al.	1956	Canada	Cohort	1800	Long-term Outcomes	0.09	77
66	Black et al.	1955	UK	RCT	1300	Patient Satisfaction	0.14	84
67	Grey et al.	1954	USA	Case-control	1400	Risk Assessment	0.04	68
68	Wright et al.	1953	UK	Systematic Review	50	Meta-analysis	0.24	95
69	Lim et al.	1952	South Korea	Cross-sectional	3900	Prevalence	0.02	62
70	Clark et al.	1951	USA	RCT	1000	Adverse Events	0.13	81
71	Wang et al.	1950	China	Observational	3200	Incidence	0.07	73
72	Nguyen et al.	1949	Vietnam	Cohort	2100	Healthcare Costs	0.08	76
73	Anderson et al.	1948	Australia	RCT	1100	Compliance	0.16	86
74	Kim et al.	1947	Japan	Longitudinal	2300	Healthcare Costs	0.06	74
75	Miller et al.	1946	USA	Systematic Review	60	Meta-analysis	0.27	97
76	Green et al.	1945	UK	RCT	1200	Side Effects	0.10	79
77	Brown et al.	1944	USA	Observational	2700	Healthcare Utilization	0.05	67
78	White et al.	1943	Canada	Cohort	1900	Long-term Outcomes	0.09	77
79	Black et al.	1942	UK	RCT	1300	Patient Satisfaction	0.14	84
80	Grey et al.	1941	USA	Case-control	1400	Risk Assessment	0.04	68
81	Wright et al.	1940	UK	Systematic Review	65	Meta-analysis	0.25	96
82	Lim et al.	1939	South Korea	Cross-sectional	4000	Prevalence	0.02	63
83	Clark et al.	1938	USA	RCT	1000	Adverse Events	0.13	81
84	Wang et al.	1937	China	Observational	3300	Incidence	0.07	73
85	Nguyen et al.	1936	Vietnam	Cohort	2200	Healthcare Costs	0.08	76
86	Anderson et al.	1935	Australia	RCT	1100	Compliance	0.16	86
87	Kim et al.	1934	Japan	Longitudinal	2400	Healthcare Costs	0.06	74
88	Miller et al.	1933	USA	Systematic Review	70	Meta-analysis	0.28	98
89	Green et al.	1932	UK	RCT	1200	Side Effects	0.10	79
90	Brown et al.	1931	USA	Observational	2800	Healthcare Utilization	0.05	67
91	White et al.	1930	Canada	Cohort	2000	Long-term Outcomes	0.09	77
92	Black et al.	1929	UK	RCT	1300	Patient Satisfaction	0.14	84
93	Grey et al.	1928	USA	Case-control	1400	Risk Assessment	0.04	68
94	Wright et al.	1927	UK	Systematic Review	75	Meta-analysis	0.26	97
95	Lim et al.	1926	South Korea	Cross-sectional	4100	Prevalence	0.02	64
96	Clark et al.	1925	USA	RCT	1000	Adverse Events	0.13	81
97	Wang et al.	1924	China	Observational	3400	Incidence	0.07	73
98	Nguyen et al.	1923	Vietnam	Cohort	2300	Healthcare Costs	0.08	76
99	Anderson et al.	1922	Australia	RCT	1100	Compliance	0.16	86
100	Kim et al.	1921	Japan	Longitudinal	2500	Healthcare Costs	0.06	74

Study	Author	Year	Country	Design	Sample Size	Intervention	Comparison	Outcome	Quality Score
1	Smith et al.	2018	USA	RCT	1000	Group A	Group B	Primary	High
2	Jones et al.	2019	UK	Cohort	5000	Group A	Group B	Secondary	Medium
3	Lee et al.	2020	Canada	RCT	2000	Group A	Group B	Primary	High
4	Kim et al.	2017	South Korea	Case-control	3000	Group A	Group B	Secondary	Medium
5	Patel et al.	2019	India	RCT	1500	Group A	Group B	Primary	High
6	Wilson et al.	2018	Australia	Cohort	4000	Group A	Group B	Secondary	Medium
7	Nguyen et al.	2020	Vietnam	RCT	1200	Group A	Group B	Primary	High
8	Chen et al.	2019	China	Case-control	2500	Group A	Group B	Secondary	Medium
9	Miller et al.	2018	USA	RCT	800	Group A	Group B	Primary	High
10	Roberts et al.	2017	UK	Cohort	6000	Group A	Group B	Secondary	Medium
11	Wang et al.	2020	China	RCT	1800	Group A	Group B	Primary	High
12	Thompson et al.	2019	USA	Case-control	3500	Group A	Group B	Secondary	Medium
13	Anderson et al.	2018	UK	RCT	900	Group A	Group B	Primary	High
14	Green et al.	2017	USA	Cohort	7000	Group A	Group B	Secondary	Medium
15	White et al.	2020	Canada	RCT	1100	Group A	Group B	Primary	High
16	Harris et al.	2019	UK	Case-control	2800	Group A	Group B	Secondary	Medium
17	Clark et al.	2018	USA	RCT	1300	Group A	Group B	Primary	High
18	Ross et al.	2017	UK	Cohort	5500	Group A	Group B	Secondary	Medium
19	Foster et al.	2020	USA	RCT	1600	Group A	Group B	Primary	High
20	Reed et al.	2019	UK	Case-control	3200	Group A	Group B	Secondary	Medium
21	Greenwood et al.	2018	USA	RCT	1400	Group A	Group B	Primary	High
22	Wright et al.	2017	UK	Cohort	6500	Group A	Group B	Secondary	Medium
23	Phillips et al.	2020	Canada	RCT	1000	Group A	Group B	Primary	High
24	Carter et al.	2019	UK	Case-control	2900	Group A	Group B	Secondary	Medium
25	Evans et al.	2018	USA	RCT	1200	Group A	Group B	Primary	High
26	Turner et al.	2017	UK	Cohort	5800	Group A	Group B	Secondary	Medium
27	Black et al.	2020	USA	RCT	1700	Group A	Group B	Primary	High
28	Scott et al.	2019	UK	Case-control	3100	Group A	Group B	Secondary	Medium
29	Young et al.	2018	USA	RCT	1100	Group A	Group B	Primary	High
30	King et al.	2017	UK	Cohort	6200	Group A	Group B	Secondary	Medium
31	Wells et al.	2020	Canada	RCT	1300	Group A	Group B	Primary	High
32	Alvarez et al.	2019	Spain	Case-control	2700	Group A	Group B	Secondary	Medium
33	Chen et al.	2018	China	RCT	1500	Group A	Group B	Primary	High
34	Wang et al.	2017	China	Cohort	7500	Group A	Group B	Secondary	Medium
35	Lee et al.	2020	South Korea	RCT	1400	Group A	Group B	Primary	High
36	Kim et al.	2019	South Korea	Case-control	3300	Group A	Group B	Secondary	Medium
37	Patel et al.	2018	India	RCT	1600	Group A	Group B	Primary	High
38	Wilson et al.	2017	Australia	Cohort	6800	Group A	Group B	Secondary	Medium
39	Nguyen et al.	2020	Vietnam	RCT	1200	Group A	Group B	Primary	High
40	Chen et al.	2019	China	Case-control	3400	Group A	Group B	Secondary	Medium
41	Miller et al.	2018	USA	RCT	900	Group A	Group B	Primary	High
42	Roberts et al.	2017	UK	Cohort	6300	Group A	Group B	Secondary	Medium
43	Wang et al.	2020	China	RCT	1800	Group A	Group B	Primary	High
44	Thompson et al.	2019	USA	Case-control	3600	Group A	Group B	Secondary	Medium
45	Anderson et al.	2018	UK	RCT	1000	Group A	Group B	Primary	High
46	Green et al.	2017	USA	Cohort	7200	Group A	Group B	Secondary	Medium
47	White et al.	2020	Canada	RCT	1100	Group A	Group B	Primary	High
48	Harris et al.	2019	UK	Case-control	3000	Group A	Group B	Secondary	Medium
49	Clark et al.	2018	USA	RCT	1300	Group A	Group B	Primary	High
50	Ross et al.	2017	UK	Cohort	5900	Group A	Group B	Secondary	Medium
51	Foster et al.	2020	USA	RCT	1600	Group A	Group B	Primary	High
52	Reed et al.	2019	UK	Case-control	3200	Group A	Group B	Secondary	Medium
53	Greenwood et al.	2018	USA	RCT	1400	Group A	Group B	Primary	High
54	Wright et al.	2017	UK	Cohort	6600	Group A	Group B	Secondary	Medium
55	Phillips et al.	2020	Canada	RCT	1000	Group A	Group B	Primary	High
56	Carter et al.	2019	UK	Case-control	2900	Group A	Group B	Secondary	Medium
57	Evans et al.	2018	USA	RCT	1200	Group A	Group B	Primary	High
58	Turner et al.	2017	UK	Cohort	5800	Group A	Group B	Secondary	Medium
59	Black et al.	2020	USA	RCT	1700	Group A	Group B	Primary	High
60	Scott et al.	2019	UK	Case-control	3100	Group A	Group B	Secondary	Medium
61	Young et al.	2018	USA	RCT	1100	Group A	Group B	Primary	High
62	King et al.	2017	UK	Cohort	6200	Group A	Group B	Secondary	Medium
63	Wells et al.	2020	Canada	RCT	1300	Group A	Group B	Primary	High
64	Alvarez et al.	2019	Spain	Case-control	2700	Group A	Group B	Secondary	Medium
65	Chen et al.	2018	China	RCT	1500	Group A	Group B	Primary	High
66	Wang et al.	2017	China	Cohort	7500	Group A	Group B	Secondary	Medium
67	Lee et al.	2020	South Korea	RCT	1400	Group A	Group B	Primary	High
68	Kim et al.	2019	South Korea	Case-control	3300	Group A	Group B	Secondary	Medium
69	Patel et al.	2018	India	RCT	1600	Group A	Group B	Primary	High
70	Wilson et al.	2017	Australia	Cohort	6800	Group A	Group B	Secondary	Medium
71	Nguyen et al.	2020	Vietnam	RCT	1200	Group A	Group B	Primary	High
72	Chen et al.	2019	China	Case-control	3400	Group A	Group B	Secondary	Medium
73	Miller et al.	2018	USA	RCT	900	Group A	Group B	Primary	High
74	Roberts et al.	2017	UK	Cohort	6300	Group A	Group B	Secondary	Medium
75	Wang et al.	2020	China	RCT	1800	Group A	Group B	Primary	High
76	Thompson et al.	2019	USA	Case-control	3600	Group A	Group B	Secondary	Medium
77	Anderson et al.	2018	UK	RCT	1000	Group A	Group B	Primary	High
78	Green et al.	2017	USA	Cohort	7200	Group A	Group B	Secondary	Medium
79	White et al.	2020	Canada	RCT	1100	Group A	Group B	Primary	High
80	Harris et al.	2019	UK	Case-control	3000	Group A	Group B	Secondary	Medium
81	Clark et al.	2018	USA	RCT	1300	Group A	Group B	Primary	High
82	Ross et al.	2017	UK	Cohort	5900	Group A	Group B	Secondary	Medium
83	Foster et al.	2020	USA	RCT	1600	Group A	Group B	Primary	High
84	Reed et al.	2019	UK	Case-control	3200	Group A	Group B	Secondary	Medium
85	Greenwood et al.	2018	USA	RCT	1400	Group A	Group B	Primary	High
86	Wright et al.	2017	UK	Cohort	6600	Group A	Group B	Secondary	Medium
87	Phillips et al.	2020	Canada	RCT	1000	Group A	Group B	Primary	High
88	Carter et al.	2019	UK	Case-control	2900	Group A	Group B	Secondary	Medium
89	Evans et al.	2018	USA	RCT	1200	Group A	Group B	Primary	High
90	Turner et al.	2017	UK	Cohort	5800	Group A	Group B	Secondary	Medium
91	Black et al.	2020	USA	RCT	1700	Group A	Group B	Primary	High
92	Scott et al.	2019	UK	Case-control	3100	Group A	Group B	Secondary	Medium
93	Young et al.	2018	USA	RCT	1100	Group A	Group B	Primary	High
94	King et al.	2017	UK	Cohort	6200	Group A	Group B	Secondary	Medium
95	Wells et al.	2020	Canada	RCT	1300	Group A	Group B	Primary	High
96	Alvarez et al.	2019	Spain	Case-control	2700	Group A	Group B	Secondary	Medium
97	Chen et al.	2018	China	RCT	1500	Group A	Group B	Primary	High
98	Wang et al.	2017	China	Cohort	7500	Group A	Group B	Secondary	Medium
99	Lee et al.	2020	South Korea	RCT	1400	Group A	Group B	Primary	High
100	Kim et al.	2019	South Korea	Case-control	3300	Group A	Group B	Secondary	Medium

Study	Year	Country	Sample Size	Prevalence (%)	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
1	2018	India	200	10.5	6.8-16.2	1.0	1.0	1.0	1.0	1.0	1.0
2	2019	India	350	12.3	8.5-18.0	1.2	0.8-1.8	1.2	0.8-1.8	1.2	0.8-1.8
3	2020	India	400	11.8	7.9-17.5	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
4	2017	India	150	9.2	5.8-14.6	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
5	2018	India	250	10.8	7.1-16.5	1.0	1.0	1.0	1.0	1.0	1.0
6	2019	India	300	11.5	7.6-17.2	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
7	2020	India	350	12.1	8.2-17.8	1.2	0.8-1.8	1.2	0.8-1.8	1.2	0.8-1.8
8	2018	India	220	10.1	6.4-15.8	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
9	2019	India	280	11.2	7.3-17.0	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
10	2020	India	320	11.9	7.9-17.6	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
11	2017	India	180	9.8	6.1-15.5	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
12	2018	India	240	10.6	6.9-16.3	1.0	1.0	1.0	1.0	1.0	1.0
13	2019	India	290	11.4	7.5-17.1	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
14	2020	India	340	12.0	8.1-17.7	1.2	0.8-1.8	1.2	0.8-1.8	1.2	0.8-1.8
15	2018	India	210	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
16	2019	India	260	11.1	7.2-16.8	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
17	2020	India	310	11.7	7.7-17.4	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
18	2017	India	170	9.6	5.9-15.3	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
19	2018	India	230	10.4	6.7-16.1	1.0	1.0	1.0	1.0	1.0	1.0
20	2019	India	270	11.3	7.4-17.0	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
21	2020	India	330	12.2	8.3-17.9	1.2	0.8-1.8	1.2	0.8-1.8	1.2	0.8-1.8
22	2018	India	200	10.2	6.5-15.8	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
23	2019	India	250	11.0	7.1-16.7	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
24	2020	India	300	11.6	7.6-17.3	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
25	2017	India	160	9.4	5.7-15.1	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
26	2018	India	220	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
27	2019	India	260	11.1	7.2-16.8	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
28	2020	India	310	11.7	7.7-17.4	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
29	2018	India	210	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
30	2019	India	250	11.0	7.1-16.7	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
31	2020	India	300	11.6	7.6-17.3	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
32	2017	India	160	9.4	5.7-15.1	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
33	2018	India	220	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
34	2019	India	260	11.1	7.2-16.8	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
35	2020	India	310	11.7	7.7-17.4	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
36	2018	India	210	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
37	2019	India	250	11.0	7.1-16.7	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
38	2020	India	300	11.6	7.6-17.3	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
39	2017	India	160	9.4	5.7-15.1	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
40	2018	India	220	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
41	2019	India	260	11.1	7.2-16.8	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
42	2020	India	310	11.7	7.7-17.4	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
43	2018	India	210	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
44	2019	India	250	11.0	7.1-16.7	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
45	2020	India	300	11.6	7.6-17.3	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
46	2017	India	160	9.4	5.7-15.1	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
47	2018	India	220	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4
48	2019	India	260	11.1	7.2-16.8	1.0	0.7-1.7	1.0	0.7-1.7	1.0	0.7-1.7
49	2020	India	310	11.7	7.7-17.4	1.1	0.7-1.7	1.1	0.7-1.7	1.1	0.7-1.7
50	2018	India	210	10.3	6.6-15.9	0.9	0.6-1.4	0.9	0.6-1.4	0.9	0.6-1.4


Study	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Prevalence	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study	Author	Year	Country	Sample Size	Prevalence	95% CI	OR	95% CI	OR	95% CI
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study ID	Author	Year	Country	Design	Sample Size	Intervention	Comparison	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	120	Group A	Group B	Primary	0.15	85
2	Johnson et al.	2019	UK	Cohort	250	Group A	Group B	Primary	0.20	78
3	Chen et al.	2020	China	RCT	180	Group A	Group B	Primary	0.10	92
4	Patel et al.	2017	India	Quasi-expt	300	Group A	Group B	Primary	0.18	70
5	Lee et al.	2019	South Korea	RCT	150	Group A	Group B	Primary	0.12	88
6	Nguyen et al.	2018	Vietnam	Cohort	200	Group A	Group B	Primary	0.22	75
7	Wang et al.	2020	China	RCT	160	Group A	Group B	Primary	0.14	90
8	Almeida et al.	2019	Brazil	Quasi-expt	280	Group A	Group B	Primary	0.16	72
9	Kim et al.	2018	South Korea	RCT	140	Group A	Group B	Primary	0.11	87
10	De Silva et al.	2019	Sri Lanka	Cohort	220	Group A	Group B	Primary	0.19	76
11	Okonkwo et al.	2020	Nigeria	RCT	170	Group A	Group B	Primary	0.13	89
12	Yamamoto et al.	2018	Japan	Quasi-expt	290	Group A	Group B	Primary	0.17	71
13	Nguyen et al.	2019	Vietnam	RCT	155	Group A	Group B	Primary	0.12	88
14	Chen et al.	2020	China	Cohort	210	Group A	Group B	Primary	0.21	77
15	Patel et al.	2018	India	RCT	165	Group A	Group B	Primary	0.14	91
16	Lee et al.	2019	South Korea	Quasi-expt	270	Group A	Group B	Primary	0.16	73
17	Nguyen et al.	2020	Vietnam	RCT	145	Group A	Group B	Primary	0.11	87
18	Wang et al.	2018	China	Cohort	230	Group A	Group B	Primary	0.20	79
19	Almeida et al.	2019	Brazil	RCT	150	Group A	Group B	Primary	0.12	88
20	Kim et al.	2020	South Korea	Quasi-expt	280	Group A	Group B	Primary	0.17	72
21	De Silva et al.	2018	Sri Lanka	RCT	140	Group A	Group B	Primary	0.11	87
22	Okonkwo et al.	2019	Nigeria	Cohort	240	Group A	Group B	Primary	0.19	76
23	Yamamoto et al.	2020	Japan	RCT	160	Group A	Group B	Primary	0.14	90
24	Nguyen et al.	2018	Vietnam	Quasi-expt	290	Group A	Group B	Primary	0.17	71
25	Chen et al.	2019	China	RCT	155	Group A	Group B	Primary	0.12	88
26	Patel et al.	2020	India	Cohort	210	Group A	Group B	Primary	0.21	77
27	Lee et al.	2018	South Korea	RCT	165	Group A	Group B	Primary	0.14	91
28	Nguyen et al.	2019	Vietnam	Quasi-expt	270	Group A	Group B	Primary	0.16	73
29	Wang et al.	2020	China	RCT	145	Group A	Group B	Primary	0.11	87
30	Almeida et al.	2018	Brazil	Cohort	230	Group A	Group B	Primary	0.20	79
31	Kim et al.	2019	South Korea	RCT	150	Group A	Group B	Primary	0.12	88
32	De Silva et al.	2020	Sri Lanka	Quasi-expt	280	Group A	Group B	Primary	0.17	72
33	Okonkwo et al.	2018	Nigeria	RCT	140	Group A	Group B	Primary	0.11	87
34	Yamamoto et al.	2019	Japan	Cohort	240	Group A	Group B	Primary	0.19	76
35	Nguyen et al.	2020	Vietnam	RCT	160	Group A	Group B	Primary	0.14	90
36	Chen et al.	2018	China	Quasi-expt	290	Group A	Group B	Primary	0.17	71
37	Patel et al.	2019	India	RCT	155	Group A	Group B	Primary	0.12	88
38	Lee et al.	2020	South Korea	Cohort	210	Group A	Group B	Primary	0.21	77
39	Nguyen et al.	2018	Vietnam	RCT	165	Group A	Group B	Primary	0.14	91
40	Wang et al.	2019	China	Quasi-expt	270	Group A	Group B	Primary	0.16	73
41	Almeida et al.	2020	Brazil	RCT	145	Group A	Group B	Primary	0.11	87
42	Kim et al.	2018	South Korea	Cohort	230	Group A	Group B	Primary	0.20	79
43	De Silva et al.	2019	Sri Lanka	RCT	150	Group A	Group B	Primary	0.12	88
44	Okonkwo et al.	2020	Nigeria	Quasi-expt	280	Group A	Group B	Primary	0.17	72
45	Yamamoto et al.	2018	Japan	RCT	140	Group A	Group B	Primary	0.11	87
46	Nguyen et al.	2019	Vietnam	Cohort	240	Group A	Group B	Primary	0.19	76
47	Chen et al.	2020	China	RCT	160	Group A	Group B	Primary	0.14	90
48	Patel et al.	2018	India	Quasi-expt	290	Group A	Group B	Primary	0.17	71
49	Lee et al.	2019	South Korea	RCT	155	Group A	Group B	Primary	0.12	88
50	Nguyen et al.	2020	Vietnam	Cohort	210	Group A	Group B	Primary	0.21	77
51	Wang et al.	2018	China	RCT	165	Group A	Group B	Primary	0.14	91
52	Almeida et al.	2019	Brazil	Quasi-expt	270	Group A	Group B	Primary	0.16	73
53	Kim et al.	2020	South Korea	RCT	145	Group A	Group B	Primary	0.11	87
54	De Silva et al.	2018	Sri Lanka	Cohort	230	Group A	Group B	Primary	0.20	79
55	Okonkwo et al.	2019	Nigeria	RCT	150	Group A	Group B	Primary	0.12	88
56	Yamamoto et al.	2020	Japan	Quasi-expt	280	Group A	Group B	Primary	0.17	72
57	Nguyen et al.	2018	Vietnam	RCT	140	Group A	Group B	Primary	0.11	87
58	Chen et al.	2019	China	Cohort	240	Group A	Group B	Primary	0.19	76
59	Patel et al.	2020	India	RCT	160	Group A	Group B	Primary	0.14	90
60	Lee et al.	2018	South Korea	Quasi-expt	290	Group A	Group B	Primary	0.17	71
61	Nguyen et al.	2019	Vietnam	RCT	155	Group A	Group B	Primary	0.12	88
62	Wang et al.	2020	China	Cohort	210	Group A	Group B	Primary	0.21	77
63	Almeida et al.	2018	Brazil	RCT	165	Group A	Group B	Primary	0.14	91
64	Kim et al.	2019	South Korea	Quasi-expt	270	Group A	Group B	Primary	0.16	73
65	De Silva et al.	2020	Sri Lanka	RCT	145	Group A	Group B	Primary	0.11	87
66	Okonkwo et al.	2018	Nigeria	Cohort	230	Group A	Group B	Primary	0.20	79
67	Yamamoto et al.	2019	Japan	RCT	150	Group A	Group B	Primary	0.12	88
68	Nguyen et al.	2020	Vietnam	Quasi-expt	280	Group A	Group B	Primary	0.17	72
69	Chen et al.	2018	China	RCT	140	Group A	Group B	Primary	0.11	87
70	Patel et al.	2019	India	Cohort	240	Group A	Group B	Primary	0.19	76
71	Lee et al.	2020	South Korea	RCT	160	Group A	Group B	Primary	0.14	90
72	Nguyen et al.	2018	Vietnam	Quasi-expt	290	Group A	Group B	Primary	0.17	71
73	Wang et al.	2019	China	RCT	155	Group A	Group B	Primary	0.12	88
74	Almeida et al.	2020	Brazil	Cohort	210	Group A	Group B	Primary	0.21	77
75	Kim et al.	2018	South Korea	RCT	165	Group A	Group B	Primary	0.14	91
76	De Silva et al.	2019	Sri Lanka	Quasi-expt	270	Group A	Group B	Primary	0.16	73
77	Okonkwo et al.	2020	Nigeria	RCT	145	Group A	Group B	Primary	0.11	87
78	Yamamoto et al.	2018	Japan	Cohort	230	Group A	Group B	Primary	0.20	79
79	Nguyen et al.	2019	Vietnam	RCT	150	Group A	Group B	Primary	0.12	88
80	Chen et al.	2020	China	Quasi-expt	280	Group A	Group B	Primary	0.17	72
81	Patel et al.	2018	India	RCT	140	Group A	Group B	Primary	0.11	87
82	Lee et al.	2019	South Korea	Cohort	240	Group A	Group B	Primary	0.19	76
83	Nguyen et al.	2020	Vietnam	RCT	160	Group A	Group B	Primary	0.14	90
84	Wang et al.	2018	China	Quasi-expt	290	Group A	Group B	Primary	0.17	71
85	Almeida et al.	2019	Brazil	RCT	155	Group A	Group B	Primary	0.12	88
86	Kim et al.	2020	South Korea	Cohort	210	Group A	Group B	Primary	0.21	77
87	De Silva et al.	2018	Sri Lanka	RCT	165	Group A	Group B	Primary	0.14	91
88	Okonkwo et al.	2019	Nigeria	Quasi-expt	270	Group A	Group B	Primary	0.16	73
89	Yamamoto et al.	2020	Japan	RCT	145	Group A	Group B	Primary	0.11	87
90	Nguyen et al.	2018	Vietnam	Cohort	230	Group A	Group B	Primary	0.20	79
91	Chen et al.	2019	China	RCT	150	Group A	Group B	Primary	0.12	88
92	Patel et al.	2020	India	Quasi-expt	280	Group A	Group B	Primary	0.17	72
93	Lee et al.	2018	South Korea	RCT	140	Group A	Group B	Primary	0.11	87
94	Nguyen et al.	2019	Vietnam	Cohort	240	Group A	Group B	Primary	0.19	76
95	Wang et al.	2020	China	RCT	160	Group A	Group B	Primary	0.14	90
96	Almeida et al.	2018	Brazil	Quasi-expt	290	Group A	Group B	Primary	0.17	71
97	Kim et al.	2019	South Korea	RCT	155	Group A	Group B	Primary	0.12	88
98	De Silva et al.	2020	Sri Lanka	Cohort	210	Group A	Group B	Primary	0.21	77
99	Okonkwo et al.	2018	Nigeria	RCT	165	Group A	Group B	Primary	0.14	91
100	Yamamoto et al.	2019	Japan	Quasi-expt	270	Group A	Group B	Primary	0.16	73

Study	Author	Year	Country	Design	Sample Size	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	1200	Survival	0.15	12
2	Johnson et al.	2019	UK	Cohort	2500	Quality of Life	0.20	10
3	Chen et al.	2020	China	RCT	800	Mortality	0.10	11
4	Patel et al.	2017	India	Observational	3000	Incidence	0.08	9
5	Kim et al.	2019	South Korea	RCT	1500	Adverse Events	0.12	13
6	Nguyen et al.	2018	Vietnam	Cohort	1800	Prevalence	0.05	8
7	Wang et al.	2020	China	RCT	900	Survival	0.18	14
8	Lee et al.	2019	South Korea	Observational	2200	Quality of Life	0.15	10
9	Alam et al.	2018	Bangladesh	Cohort	1600	Mortality	0.07	9
10	De Silva et al.	2019	Sri Lanka	RCT	1100	Adverse Events	0.11	12
11	Okonkwo et al.	2017	Nigeria	Observational	2800	Incidence	0.06	8
12	Yamamoto et al.	2018	Japan	RCT	1300	Survival	0.14	11
13	Abdullah et al.	2019	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
14	Nguyen et al.	2020	Vietnam	RCT	1400	Mortality	0.13	13
15	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
16	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12
17	Kim et al.	2017	South Korea	Cohort	1900	Mortality	0.09	9
18	Nguyen et al.	2018	Vietnam	RCT	1700	Quality of Life	0.21	11
19	Wang et al.	2019	China	Observational	2900	Incidence	0.05	8
20	Lee et al.	2018	South Korea	RCT	1200	Adverse Events	0.17	13
21	Alam et al.	2019	Bangladesh	Cohort	1700	Mortality	0.08	9
22	De Silva et al.	2017	Sri Lanka	RCT	1100	Quality of Life	0.22	12
23	Okonkwo et al.	2018	Nigeria	Observational	2700	Incidence	0.06	8
24	Yamamoto et al.	2019	Japan	RCT	1300	Survival	0.14	11
25	Abdullah et al.	2018	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
26	Nguyen et al.	2019	Vietnam	RCT	1400	Mortality	0.13	13
27	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
28	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12
29	Kim et al.	2017	South Korea	Cohort	1900	Mortality	0.09	9
30	Nguyen et al.	2018	Vietnam	RCT	1700	Quality of Life	0.21	11
31	Wang et al.	2019	China	Observational	2900	Incidence	0.05	8
32	Lee et al.	2018	South Korea	RCT	1200	Adverse Events	0.17	13
33	Alam et al.	2019	Bangladesh	Cohort	1700	Mortality	0.08	9
34	De Silva et al.	2017	Sri Lanka	RCT	1100	Quality of Life	0.22	12
35	Okonkwo et al.	2018	Nigeria	Observational	2700	Incidence	0.06	8
36	Yamamoto et al.	2019	Japan	RCT	1300	Survival	0.14	11
37	Abdullah et al.	2018	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
38	Nguyen et al.	2019	Vietnam	RCT	1400	Mortality	0.13	13
39	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
40	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12
41	Kim et al.	2017	South Korea	Cohort	1900	Mortality	0.09	9
42	Nguyen et al.	2018	Vietnam	RCT	1700	Quality of Life	0.21	11
43	Wang et al.	2019	China	Observational	2900	Incidence	0.05	8
44	Lee et al.	2018	South Korea	RCT	1200	Adverse Events	0.17	13
45	Alam et al.	2019	Bangladesh	Cohort	1700	Mortality	0.08	9
46	De Silva et al.	2017	Sri Lanka	RCT	1100	Quality of Life	0.22	12
47	Okonkwo et al.	2018	Nigeria	Observational	2700	Incidence	0.06	8
48	Yamamoto et al.	2019	Japan	RCT	1300	Survival	0.14	11
49	Abdullah et al.	2018	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
50	Nguyen et al.	2019	Vietnam	RCT	1400	Mortality	0.13	13
51	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
52	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12
53	Kim et al.	2017	South Korea	Cohort	1900	Mortality	0.09	9
54	Nguyen et al.	2018	Vietnam	RCT	1700	Quality of Life	0.21	11
55	Wang et al.	2019	China	Observational	2900	Incidence	0.05	8
56	Lee et al.	2018	South Korea	RCT	1200	Adverse Events	0.17	13
57	Alam et al.	2019	Bangladesh	Cohort	1700	Mortality	0.08	9
58	De Silva et al.	2017	Sri Lanka	RCT	1100	Quality of Life	0.22	12
59	Okonkwo et al.	2018	Nigeria	Observational	2700	Incidence	0.06	8
60	Yamamoto et al.	2019	Japan	RCT	1300	Survival	0.14	11
61	Abdullah et al.	2018	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
62	Nguyen et al.	2019	Vietnam	RCT	1400	Mortality	0.13	13
63	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
64	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12
65	Kim et al.	2017	South Korea	Cohort	1900	Mortality	0.09	9
66	Nguyen et al.	2018	Vietnam	RCT	1700	Quality of Life	0.21	11
67	Wang et al.	2019	China	Observational	2900	Incidence	0.05	8
68	Lee et al.	2018	South Korea	RCT	1200	Adverse Events	0.17	13
69	Alam et al.	2019	Bangladesh	Cohort	1700	Mortality	0.08	9
70	De Silva et al.	2017	Sri Lanka	RCT	1100	Quality of Life	0.22	12
71	Okonkwo et al.	2018	Nigeria	Observational	2700	Incidence	0.06	8
72	Yamamoto et al.	2019	Japan	RCT	1300	Survival	0.14	11
73	Abdullah et al.	2018	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
74	Nguyen et al.	2019	Vietnam	RCT	1400	Mortality	0.13	13
75	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
76	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12
77	Kim et al.	2017	South Korea	Cohort	1900	Mortality	0.09	9
78	Nguyen et al.	2018	Vietnam	RCT	1700	Quality of Life	0.21	11
79	Wang et al.	2019	China	Observational	2900	Incidence	0.05	8
80	Lee et al.	2018	South Korea	RCT	1200	Adverse Events	0.17	13
81	Alam et al.	2019	Bangladesh	Cohort	1700	Mortality	0.08	9
82	De Silva et al.	2017	Sri Lanka	RCT	1100	Quality of Life	0.22	12
83	Okonkwo et al.	2018	Nigeria	Observational	2700	Incidence	0.06	8
84	Yamamoto et al.	2019	Japan	RCT	1300	Survival	0.14	11
85	Abdullah et al.	2018	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
86	Nguyen et al.	2019	Vietnam	RCT	1400	Mortality	0.13	13
87	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
88	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12
89	Kim et al.	2017	South Korea	Cohort	1900	Mortality	0.09	9
90	Nguyen et al.	2018	Vietnam	RCT	1700	Quality of Life	0.21	11
91	Wang et al.	2019	China	Observational	2900	Incidence	0.05	8
92	Lee et al.	2018	South Korea	RCT	1200	Adverse Events	0.17	13
93	Alam et al.	2019	Bangladesh	Cohort	1700	Mortality	0.08	9
94	De Silva et al.	2017	Sri Lanka	RCT	1100	Quality of Life	0.22	12
95	Okonkwo et al.	2018	Nigeria	Observational	2700	Incidence	0.06	8
96	Yamamoto et al.	2019	Japan	RCT	1300	Survival	0.14	11
97	Abdullah et al.	2018	Saudi Arabia	Cohort	2000	Quality of Life	0.19	10
98	Nguyen et al.	2019	Vietnam	RCT	1400	Mortality	0.13	13
99	Chen et al.	2018	China	Observational	3200	Prevalence	0.04	7
100	Patel et al.	2019	India	RCT	1000	Adverse Events	0.16	12

Study ID	Author(s)	Year	Country	Design	Sample Size	Intervention	Comparison	Outcome	Effect Size	Quality Score
1	Smith et al.	2018	USA	RCT	120	Group A	Group B	Primary	0.15	85
2	Johnson et al.	2019	UK	Observational	250	Group C	Group D	Secondary	0.22	72
3	Chen et al.	2020	China	RCT	180	Group E	Group F	Primary	0.18	88
4	Patel et al.	2017	India	Observational	300	Group G	Group H	Secondary	0.25	68
5	Kim et al.	2019	South Korea	RCT	150	Group I	Group J	Primary	0.12	82
6	Nguyen et al.	2018	Vietnam	Observational	200	Group K	Group L	Secondary	0.20	70
7	Alvarez et al.	2020	Spain	RCT	160	Group M	Group N	Primary	0.16	80
8	Williams et al.	2019	Australia	Observational	220	Group O	Group P	Secondary	0.23	75
9	Lee et al.	2018	Canada	RCT	140	Group Q	Group R	Primary	0.14	83
10	Okamoto et al.	2017	Japan	Observational	280	Group S	Group T	Secondary	0.21	73
11	Costa et al.	2019	Brazil	RCT	170	Group U	Group V	Primary	0.17	81
12	Nguyen et al.	2018	Vietnam	Observational	210	Group W	Group X	Secondary	0.19	71
13	Alvarez et al.	2020	Spain	RCT	155	Group Y	Group Z	Primary	0.155	805
14	Williams et al.	2019	Australia	Observational	225	Group AA	Group AB	Secondary	0.235	755
15	Lee et al.	2018	Canada	RCT	145	Group AC	Group AD	Primary	0.145	835
16	Okamoto et al.	2017	Japan	Observational	285	Group AE	Group AF	Secondary	0.215	735
17	Costa et al.	2019	Brazil	RCT	175	Group AG	Group AH	Primary	0.175	815
18	Nguyen et al.	2018	Vietnam	Observational	215	Group AI	Group AJ	Secondary	0.195	715
19	Alvarez et al.	2020	Spain	RCT	165	Group AK	Group AL	Primary	0.165	805
20	Williams et al.	2019	Australia	Observational	230	Group AM	Group AN	Secondary	0.24	76
21	Lee et al.	2018	Canada	RCT	150	Group AO	Group AP	Primary	0.15	84
22	Okamoto et al.	2017	Japan	Observational	290	Group AQ	Group AR	Secondary	0.22	74
23	Costa et al.	2019	Brazil	RCT	180	Group AS	Group AT	Primary	0.18	82
24	Nguyen et al.	2018	Vietnam	Observational	220	Group AU	Group AV	Secondary	0.20	72
25	Alvarez et al.	2020	Spain	RCT	170	Group AW	Group AX	Primary	0.17	81
26	Williams et al.	2019	Australia	Observational	235	Group AY	Group AZ	Secondary	0.245	765
27	Lee et al.	2018	Canada	RCT	155	Group BA	Group BB	Primary	0.155	845
28	Okamoto et al.	2017	Japan	Observational	295	Group BC	Group BD	Secondary	0.225	745
29	Costa et al.	2019	Brazil	RCT	185	Group BE	Group BF	Primary	0.185	825
30	Nguyen et al.	2018	Vietnam	Observational	225	Group BG	Group BH	Secondary	0.205	725
31	Alvarez et al.	2020	Spain	RCT	175	Group BI	Group BJ	Primary	0.175	815
32	Williams et al.	2019	Australia	Observational	240	Group BK	Group BL	Secondary	0.25	77
33	Lee et al.	2018	Canada	RCT	160	Group BM	Group BN	Primary	0.16	85
34	Okamoto et al.	2017	Japan	Observational	300	Group BO	Group BP	Secondary	0.23	75
35	Costa et al.	2019	Brazil	RCT	190	Group BQ	Group BR	Primary	0.19	83
36	Nguyen et al.	2018	Vietnam	Observational	230	Group BS	Group BT	Secondary	0.21	73
37	Alvarez et al.	2020	Spain	RCT	180	Group BU	Group BV	Primary	0.18	82
38	Williams et al.	2019	Australia	Observational	245	Group BW	Group BX	Secondary	0.255	775
39	Lee et al.	2018	Canada	RCT	165	Group BY	Group BZ	Primary	0.165	855
40	Okamoto et al.	2017	Japan	Observational	305	Group CA	Group CB	Secondary	0.235	755
41	Costa et al.	2019	Brazil	RCT	195	Group CC	Group CD	Primary	0.195	835
42	Nguyen et al.	2018	Vietnam	Observational	235	Group CE	Group CF	Secondary	0.215	735
43	Alvarez et al.	2020	Spain	RCT	185	Group CG	Group CH	Primary	0.185	825
44	Williams et al.	2019	Australia	Observational	250	Group CI	Group CJ	Secondary	0.26	78
45	Lee et al.	2018	Canada	RCT	170	Group CK	Group CL	Primary	0.17	86
46	Okamoto et al.	2017	Japan	Observational	310	Group CM	Group CN	Secondary	0.24	76
47	Costa et al.	2019	Brazil	RCT	200	Group CO	Group CP	Primary	0.20	84
48	Nguyen et al.	2018	Vietnam	Observational	240	Group CQ	Group CR	Secondary	0.22	74
49	Alvarez et al.	2020	Spain	RCT	190	Group CS	Group CT	Primary	0.19	83
50	Williams et al.	2019	Australia	Observational	255	Group CU	Group CV	Secondary	0.265	785
51	Lee et al.	2018	Canada	RCT	175	Group CW	Group CX	Primary	0.175	865
52	Okamoto et al.	2017	Japan	Observational	315	Group CY	Group CZ	Secondary	0.245	765
53	Costa et al.	2019	Brazil	RCT	205	Group DA	Group DB	Primary	0.205	845
54	Nguyen et al.	2018	Vietnam	Observational	245	Group DC	Group DD	Secondary	0.225	745
55	Alvarez et al.	2020	Spain	RCT	195	Group DE	Group DF	Primary	0.195	835
56	Williams et al.	2019	Australia	Observational	260	Group DG	Group DH	Secondary	0.27	79
57	Lee et al.	2018	Canada	RCT	180	Group DI	Group DJ	Primary	0.18	87
58	Okamoto et al.	2017	Japan	Observational	320	Group DK	Group DL	Secondary	0.25	77
59	Costa et al.	2019	Brazil	RCT	210	Group DM	Group DN	Primary	0.21	85
60	Nguyen et al.	2018	Vietnam	Observational	250	Group DO	Group DP	Secondary	0.23	75
61	Alvarez et al.	2020	Spain	RCT	200	Group DQ	Group DR	Primary	0.20	84
62	Williams et al.	2019	Australia	Observational	265	Group DS	Group DT	Secondary	0.275	795
63	Lee et al.	2018	Canada	RCT	185	Group DU	Group DV	Primary	0.185	875
64	Okamoto et al.	2017	Japan	Observational	325	Group DW	Group DX	Secondary	0.255	775
65	Costa et al.	2019	Brazil	RCT	215	Group DY	Group DZ	Primary	0.215	855
66	Nguyen et al.	2018	Vietnam	Observational	255	Group EA	Group EB	Secondary	0.235	755
67	Alvarez et al.	2020	Spain	RCT	205	Group EC	Group ED	Primary	0.205	845
68	Williams et al.	2019	Australia	Observational	270	Group EE	Group EF	Secondary	0.28	80
69	Lee et al.	2018	Canada	RCT	190	Group EG	Group EH	Primary	0.19	88
70	Okamoto et al.	2017	Japan	Observational	330	Group EI	Group EJ	Secondary	0.26	78
71	Costa et al.	2019	Brazil	RCT	220	Group EK	Group EL	Primary	0.22	86
72	Nguyen et al.	2018	Vietnam	Observational	260	Group EM	Group EN	Secondary	0.24	76
73	Alvarez et al.	2020	Spain	RCT	210	Group EO	Group EP	Primary	0.21	85
74	Williams et al.	2019	Australia	Observational	275	Group EQ	Group ER	Secondary	0.285	805
75	Lee et al.	2018	Canada	RCT	195	Group ES	Group ET	Primary	0.195	885
76	Okamoto et al.	2017	Japan	Observational	335	Group EV	Group EW	Secondary	0.265	785
77	Costa et al.	2019	Brazil	RCT	225	Group EX	Group EY	Primary	0.225	865
78	Nguyen et al.	2018	Vietnam	Observational	265	Group EZ	Group FA	Secondary	0.245	765
79	Alvarez et al.	2020	Spain	RCT	215	Group FB	Group FB	Primary	0.215	865
80	Williams et al.	2019	Australia	Observational	280	Group FC	Group FC	Secondary	0.29	81
81	Lee et al.	2018	Canada	RCT	200	Group FD	Group FD	Primary	0.20	89
82	Okamoto et al.	2017	Japan	Observational	340	Group FE	Group FE	Secondary	0.27	79
83	Costa et al.	2019	Brazil	RCT	230	Group FF	Group FF	Primary	0.23	87
84	Nguyen et al.	2018	Vietnam	Observational	270	Group FG	Group FG	Secondary	0.25	77
85	Alvarez et al.	2020	Spain	RCT	220	Group FH	Group FH	Primary	0.22	88
86	Williams et al.	2019	Australia	Observational	285	Group FI	Group FI	Secondary	0.295	815
87	Lee et al.	2018	Canada	RCT	205	Group FJ	Group FJ	Primary	0.205	895
88	Okamoto et al.	2017	Japan	Observational	345	Group FK	Group FK	Secondary	0.275	795
89	Costa et al.	2019	Brazil	RCT	235	Group FL	Group FL	Primary	0.235	875
90	Nguyen et al.	2018	Vietnam	Observational	275	Group FM	Group FM	Secondary	0.255	775
91	Alvarez et al.	2020	Spain	RCT	225	Group FN	Group FN	Primary	0.225	885
92	Williams et al.	2019	Australia	Observational	290	Group FO	Group FO	Secondary	0.30	82
93	Lee et al.	2018	Canada	RCT	210	Group FP	Group FP	Primary	0.21	90
94	Okamoto et al.	2017	Japan	Observational	350	Group FQ	Group FQ	Secondary	0.28	80
95	Costa et al.	2019	Brazil	RCT	240	Group FR	Group FR	Primary	0.24	88
96	Nguyen et al.	2018	Vietnam	Observational	280	Group FS	Group FS	Secondary	0.26	78
97	Alvarez et al.	2020	Spain	RCT	230	Group FT	Group FT	Primary	0.23	89
98	Williams et al.	2019	Australia	Observational	295	Group FU	Group FU	Secondary	0.305	825
99	Lee et al.	2018	Canada	RCT	215	Group FV	Group FV	Primary	0.215	905
100	Okamoto et al.	2017	Japan	Observational	355	Group FW	Group FW	Secondary	0.285	805
101	Costa et al.	2019	Brazil	RCT	245	Group FX	Group FX	Primary	0.245	885
102	Nguyen et al.	2018	Vietnam	Observational	285	Group FY	Group FY	Secondary	0.265	785
103	Alvarez et al.	2020	Spain	RCT	235	Group FZ	Group FZ	Primary	0.235	905
104	Williams et al.	2019	Australia	Observational	300	Group GA	Group GA	Secondary	0.31	83
105	Lee et al.	2018	Canada	RCT	220	Group GB	Group GB	Primary	0.22	91
106	Okamoto et al.	2017	Japan	Observational	360	Group GC	Group GC	Secondary	0.29	81
107	Costa et al.	2019	Brazil	RCT	250	Group GD	Group GD	Primary	0.25	89
108	Nguyen et al.	2018	Vietnam	Observational	290	Group GE	Group GE	Secondary	0.27	79
109	Alvarez et al.	2020	Spain	RCT	240	Group GF	Group GF	Primary	0.24	90
110	Williams et al.	2019	Australia	Observational	305	Group GF	Group GF	Secondary	0.315	835
111	Lee et al.	2018	Canada	RCT	225	Group GG	Group GG	Primary	0.225	915
112	Okamoto et al.	2017	Japan	Observational	365	Group GH	Group GH	Secondary	0.295	815
113	Costa et al.	2019	Brazil	RCT	255	Group GI	Group GI	Primary	0.255	895
114	Nguyen et al.	2018	Vietnam	Observational	295	Group GJ	Group GJ	Secondary	0.275	795
115	Alvarez et al.	2020	Spain	RCT	245	Group GK	Group GK	Primary	0.245	905
116	Williams et al.	2019	Australia	Observational	310	Group GL	Group GL	Secondary	0.32	84
117	Lee et al.	2018	Canada	RCT	230	Group GM	Group GM	Primary	0.23	92
118	Okamoto et al.	2017	Japan	Observational	370	Group GN	Group GN	Secondary	0.30	82
119	Costa et al.	2019	Brazil	RCT	260	Group GO	Group GO	Primary	0.26	90
120	Nguyen et al.	2018	Vietnam	Observational	300	Group GP	Group GP	Secondary	0.28	80
121	Alvarez et al.	2020	Spain	RCT	250	Group GQ	Group GQ	Primary	0.25	91
122	Williams et al.	2019	Australia	Observational	315	Group GR	Group GR	Secondary	0.325	845
123	Lee et al.	2018	Canada	RCT	235	Group GS	Group GS	Primary	0.235	925
124	Okamoto et al.	2017	Japan	Observational	375	Group GT	Group GT	Secondary	0.305	825
125	Costa et al.	2019	Brazil	RCT	265	Group GU	Group GU	Primary	0.265	905
126	Nguyen et al.	2018	Vietnam	Observational	305	Group GV	Group GV	Secondary	0.285	805
127	Alvarez et al.	2020	Spain	RCT	255	Group GW	Group GW	Primary	0.255	915
128	Williams et al.	2019	Australia	Observational	320	Group GX	Group GX	Secondary	0.33	85
129	Lee et al.	2018	Canada	RCT	240	Group GY	Group GY	Primary	0.24	93
130	Okamoto et al.	2017	Japan	Observational	380	Group GZ	Group GZ	Secondary	0.31	83
131	Costa et al.	2019	Brazil	RCT	270	Group HA	Group HA	Primary	0.27	91
132	Nguyen et al.	2018	Vietnam	Observational	310	Group HB	Group HB	Secondary	0.29	81
133	Alvarez et al.	2020	Spain	RCT	260	Group HC	Group HC	Primary	0.26	92
134	Williams et al.	2019	Australia	Observational	325	Group HD	Group HD	Secondary	0.335	855
135	Lee et al.	2018	Canada	RCT	245	Group HE	Group HE	Primary	0.245	935
136	Okamoto et al.	2017	Japan	Observational	385	Group HF	Group HF	Secondary	0.315	835
137	Costa et al.	2019	Brazil	RCT	275	Group HG	Group HG	Primary	0.275	915
138	Nguyen et al.	2018	Vietnam	Observational	315	Group HH	Group HH	Secondary	0.295	815
139	Alvarez et al.	2020	Spain	RCT	265	Group HI	Group HI	Primary	0.265	925
140	Williams et al.	2019	Australia	Observational	330	Group HJ	Group HJ	Secondary	0.34	86



Study ID	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Significance
1	Smith et al.	2018	USA	1200	18-30	M
2	Johnson et al.	2019	UK	800	31-45	F
3	Chen et al.	2020	China	1500	18-30	M
4	Lee et al.	2017	South Korea	900	31-45	F
5	Patel et al.	2018	India	1100	18-30	M
6	Wang et al.	2019	Japan	700	31-45	F
7	Nguyen et al.	2020	Vietnam	1300	18-30	M
8	Alvarez et al.	2017	Spain	600	31-45	F
9	Kim et al.	2018	South Korea	1000	18-30	M
10	Miller et al.	2019	USA	1400	31-45	F
11	Chen et al.	2020	China	1600	18-30	M
12	Lee et al.	2017	South Korea	850	31-45	F
13	Patel et al.	2018	India	1150	18-30	M
14	Wang et al.	2019	Japan	750	31-45	F
15	Nguyen et al.	2020	Vietnam	1350	18-30	M
16	Alvarez et al.	2017	Spain	650	31-45	F
17	Kim et al.	2018	South Korea	1050	18-30	M
18	Miller et al.	2019	USA	1450	31-45	F
19	Chen et al.	2020	China	1650	18-30	M
20	Lee et al.	2017	South Korea	900	31-45	F
21	Patel et al.	2018	India	1200	18-30	M
22	Wang et al.	2019	Japan	800	31-45	F
23	Nguyen et al.	2020	Vietnam	1400	18-30	M
24	Alvarez et al.	2017	Spain	700	31-45	F
25	Kim et al.	2018	South Korea	1100	18-30	M
26	Miller et al.	2019	USA	1500	31-45	F
27	Chen et al.	2020	China	1700	18-30	M
28	Lee et al.	2017	South Korea	950	31-45	F
29	Patel et al.	2018	India	1250	18-30	M
30	Wang et al.	2019	Japan	850	31-45	F
31	Nguyen et al.	2020	Vietnam	1450	18-30	M
32	Alvarez et al.	2017	Spain	750	31-45	F
33	Kim et al.	2018	South Korea	1150	18-30	M
34	Miller et al.	2019	USA	1550	31-45	F
35	Chen et al.	2020	China	1750	18-30	M
36	Lee et al.	2017	South Korea	1000	31-45	F
37	Patel et al.	2018	India	1300	18-30	M
38	Wang et al.	2019	Japan	900	31-45	F
39	Nguyen et al.	2020	Vietnam	1500	18-30	M
40	Alvarez et al.	2017	Spain	800	31-45	F
41	Kim et al.	2018	South Korea	1200	18-30	M
42	Miller et al.	2019	USA	1600	31-45	F
43	Chen et al.	2020	China	1800	18-30	M
44	Lee et al.	2017	South Korea	1050	31-45	F
45	Patel et al.	2018	India	1350	18-30	M
46	Wang et al.	2019	Japan	950	31-45	F
47	Nguyen et al.	2020	Vietnam	1550	18-30	M
48	Alvarez et al.	2017	Spain	850	31-45	F
49	Kim et al.	2018	South Korea	1250	18-30	M
50	Miller et al.	2019	USA	1650	31-45	F
51	Chen et al.	2020	China	1850	18-30	M
52	Lee et al.	2017	South Korea	1100	31-45	F
53	Patel et al.	2018	India	1400	18-30	M
54	Wang et al.	2019	Japan	1000	31-45	F
55	Nguyen et al.	2020	Vietnam	1600	18-30	M
56	Alvarez et al.	2017	Spain	900	31-45	F
57	Kim et al.	2018	South Korea	1300	18-30	M
58	Miller et al.	2019	USA	1700	31-45	F
59	Chen et al.	2020	China	1900	18-30	M
60	Lee et al.	2017	South Korea	1150	31-45	F
61	Patel et al.	2018	India	1450	18-30	M
62	Wang et al.	2019	Japan	1050	31-45	F
63	Nguyen et al.	2020	Vietnam	1650	18-30	M
64	Alvarez et al.	2017	Spain	950	31-45	F
65	Kim et al.	2018	South Korea	1350	18-30	M
66	Miller et al.	2019	USA	1750	31-45	F
67	Chen et al.	2020	China	1950	18-30	M
68	Lee et al.	2017	South Korea	1200	31-45	F
69	Patel et al.	2018	India	1500	18-30	M
70	Wang et al.	2019	Japan	1100	31-45	F
71	Nguyen et al.	2020	Vietnam	1700	18-30	M
72	Alvarez et al.	2017	Spain	1000	31-45	F
73	Kim et al.	2018	South Korea	1400	18-30	M
74	Miller et al.	2019	USA	1800	31-45	F
75	Chen et al.	2020	China	2000	18-30	M
76	Lee et al.	2017	South Korea	1250	31-45	F
77	Patel et al.	2018	India	1550	18-30	M
78	Wang et al.	2019	Japan	1150	31-45	F
79	Nguyen et al.	2020	Vietnam	1750	18-30	M
80	Alvarez et al.	2017	Spain	1050	31-45	F
81	Kim et al.	2018	South Korea	1450	18-30	M
82	Miller et al.	2019	USA	1850	31-45	F
83	Chen et al.	2020	China	2050	18-30	M
84	Lee et al.	2017	South Korea	1300	31-45	F
85	Patel et al.	2018	India	1600	18-30	M
86	Wang et al.	2019	Japan	1200	31-45	F
87	Nguyen et al.	2020	Vietnam	1800	18-30	M
88	Alvarez et al.	2017	Spain	1100	31-45	F
89	Kim et al.	2018	South Korea	1500	18-30	M
90	Miller et al.	2019	USA	1900	31-45	F
91	Chen et al.	2020	China	2100	18-30	M
92	Lee et al.	2017	South Korea	1350	31-45	F
93	Patel et al.	2018	India	1650	18-30	M
94	Wang et al.	2019	Japan	1250	31-45	F
95	Nguyen et al.	2020	Vietnam	1850	18-30	M
96	Alvarez et al.	2017	Spain	1150	31-45	F
97	Kim et al.	2018	South Korea	1550	18-30	M
98	Miller et al.	2019	USA	1950	31-45	F
99	Chen et al.	2020	China	2150	18-30	M
100	Lee et al.	2017	South Korea	1400	31-45	F

Study	Author	Year	Country	Sample Size	Age Group	Gender	Outcome	Significance
1	Smith et al.	2018	USA	1200	18-25	M
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Study ID	Author(s)	Year	Country	Design	Sample Size	Intervention	Comparison	Primary Outcome	Secondary Outcome	Quality Score
1	Smith J, Doe A	2018	USA	RCT	150	Group A	Group B	Effectiveness	Safety	85
2	Johnson B, Lee C	2019	UK	Observational	200	Group A	Group B	Effectiveness	Safety	70
3	Kim D, Brown E	2020	Canada	RCT	120	Group A	Group B	Effectiveness	Safety	90
4	Patel F, Garcia G	2017	India	Cohort	300	Group A	Group B	Effectiveness	Safety	65
5	Ng H, Wong I	2019	Australia	RCT	180	Group A	Group B	Effectiveness	Safety	80
6	Okamoto J, Kimura K	2018	Japan	Observational	250	Group A	Group B	Effectiveness	Safety	75
7	Patel L, Singh M	2020	UK	RCT	160	Group A	Group B	Effectiveness	Safety	88
8	Ramos N, Santos O	2019	Brazil	Cohort	220	Group A	Group B	Effectiveness	Safety	68
9	Sharma P, Sharma Q	2018	India	RCT	140	Group A	Group B	Effectiveness	Safety	82
10	Taylor R, White S	2020	USA	Observational	280	Group A	Group B	Effectiveness	Safety	72
11	Ueda T, Yamada Y	2019	Japan	RCT	170	Group A	Group B	Effectiveness	Safety	87
12	Vanderbilt W, Zhang X	2018	USA	Cohort	320	Group A	Group B	Effectiveness	Safety	67
13	Wong Y, Xu Z	2020	China	RCT	190	Group A	Group B	Effectiveness	Safety	83
14	Yamamoto A, Yoshida H	2019	Japan	Observational	240	Group A	Group B	Effectiveness	Safety	73
15	Zhang B, Zhou C	2018	China	RCT	165	Group A	Group B	Effectiveness	Safety	86
16	Adams D, Baker E	2020	USA	Cohort	310	Group A	Group B	Effectiveness	Safety	69
17	Baker G, Carter H	2019	UK	RCT	155	Group A	Group B	Effectiveness	Safety	84
18	Chen I, Clark J	2018	USA	Observational	270	Group A	Group B	Effectiveness	Safety	71
19	Clark K, Davis L	2020	Canada	RCT	135	Group A	Group B	Effectiveness	Safety	89
20	Davis M, Evans N	2019	UK	Cohort	290	Group A	Group B	Effectiveness	Safety	66
21	Evans O, Fisher P	2018	USA	RCT	175	Group A	Group B	Effectiveness	Safety	81
22	Fisher Q, Green R	2020	India	Observational	260	Group A	Group B	Effectiveness	Safety	74
23	Green S, Hill T	2019	Australia	RCT	185	Group A	Group B	Effectiveness	Safety	79
24	Hill U, Irvine V	2018	UK	Cohort	305	Group A	Group B	Effectiveness	Safety	64
25	Irvine W, Jackson X	2020	USA	RCT	160	Group A	Group B	Effectiveness	Safety	86
26	Jackson Y, King Z	2019	Canada	Observational	230	Group A	Group B	Effectiveness	Safety	76
27	King AA, Lamb B	2018	UK	RCT	150	Group A	Group B	Effectiveness	Safety	85
28	Lamb CC, Martin DD	2020	USA	Cohort	315	Group A	Group B	Effectiveness	Safety	68
29	Martin EE, Nash FF	2019	UK	RCT	165	Group A	Group B	Effectiveness	Safety	83
30	Nash GG, Owen HH	2018	USA	Observational	275	Group A	Group B	Effectiveness	Safety	72
31	Owen II, Patel JJ	2020	India	RCT	170	Group A	Group B	Effectiveness	Safety	87
32	Patel KK, Quinn LL	2019	Australia	Cohort	295	Group A	Group B	Effectiveness	Safety	67
33	Quinn MM, Ryan NN	2018	UK	RCT	155	Group A	Group B	Effectiveness	Safety	84
34	Ryan OO, Scott PP	2020	USA	Observational	265	Group A	Group B	Effectiveness	Safety	74
35	Scott QQ, Taylor RR	2019	Canada	RCT	180	Group A	Group B	Effectiveness	Safety	80
36	Taylor SS, White TT	2018	UK	Cohort	300	Group A	Group B	Effectiveness	Safety	66
37	White UU, Young VV	2020	USA	RCT	160	Group A	Group B	Effectiveness	Safety	86
38	Young WW, Zhang XX	2019	China	Observational	245	Group A	Group B	Effectiveness	Safety	73
39	Zhang YY, Zhou ZZ	2018	China	RCT	165	Group A	Group B	Effectiveness	Safety	83
40	Zhou AA, Adams BB	2020	USA	Cohort	310	Group A	Group B	Effectiveness	Safety	69
41	Adams CC, Baker DD	2019	UK	RCT	155	Group A	Group B	Effectiveness	Safety	84
42	Baker EE, Carter FF	2018	USA	Observational	270	Group A	Group B	Effectiveness	Safety	71
43	Carter GG, Clark HH	2020	Canada	RCT	135	Group A	Group B	Effectiveness	Safety	89
44	Clark II, Davis JJ	2019	UK	Cohort	290	Group A	Group B	Effectiveness	Safety	66
45	Davis KK, Evans LL	2018	USA	RCT	175	Group A	Group B	Effectiveness	Safety	81
46	Evans MM, Fisher NN	2020	India	Observational	260	Group A	Group B	Effectiveness	Safety	74
47	Fisher OO, Green PP	2019	Australia	RCT	185	Group A	Group B	Effectiveness	Safety	79
48	Green QQ, Hill RR	2018	UK	Cohort	305	Group A	Group B	Effectiveness	Safety	64
49	Hill SS, Irvine TT	2020	USA	RCT	160	Group A	Group B	Effectiveness	Safety	86
50	Irvine UU, Jackson VV	2019	Canada	Observational	230	Group A	Group B	Effectiveness	Safety	76
51	Jackson WW, King XX	2018	UK	RCT	150	Group A	Group B	Effectiveness	Safety	85
52	King YY, Lamb ZZ	2020	USA	Cohort	315	Group A	Group B	Effectiveness	Safety	68
53	Lamb AA, Martin BB	2019	UK	RCT	165	Group A	Group B	Effectiveness	Safety	83
54	Martin CC, Nash DD	2018	USA	Observational	275	Group A	Group B	Effectiveness	Safety	72
55	Nash EE, Owen FF	2020	India	RCT	170	Group A	Group B	Effectiveness	Safety	87
56	Owen GG, Patel HH	2019	Australia	Cohort	295	Group A	Group B	Effectiveness	Safety	67
57	Patel II, Quinn JJ	2018	UK	RCT	155	Group A	Group B	Effectiveness	Safety	84
58	Quinn KK, Ryan LL	2020	USA	Observational	265	Group A	Group B	Effectiveness	Safety	74
59	Ryan MM, Scott NN	2019	Canada	RCT	180	Group A	Group B	Effectiveness	Safety	80
60	Scott OO, Taylor PP	2018	UK	Cohort	300	Group A	Group B	Effectiveness	Safety	66
61	Taylor QQ, White RR	2020	USA	RCT	160	Group A	Group B	Effectiveness	Safety	86
62	White SS, Young TT	2019	China	Observational	245	Group A	Group B	Effectiveness	Safety	73
63	Young UU, Zhang VV	2018	China	RCT	165	Group A	Group B	Effectiveness	Safety	83
64	Zhang WW, Zhou XX	2020	USA	Cohort	310	Group A	Group B	Effectiveness	Safety	69
65	Zhou YY, Adams ZZ	2019	UK	RCT	155	Group A	Group B	Effectiveness	Safety	84
66	Adams AA, Baker BB	2018	USA	Observational	270	Group A	Group B	Effectiveness	Safety	71
67	Baker CC, Carter DD	2020	Canada	RCT	135	Group A	Group B	Effectiveness	Safety	89
68	Carter EE, Clark FF	2019	UK	Cohort	290	Group A	Group B	Effectiveness	Safety	66
69	Clark GG, Davis HH	2018	USA	RCT	175	Group A	Group B	Effectiveness	Safety	81
70	Davis II, Evans JJ	2020	India	Observational	260	Group A	Group B	Effectiveness	Safety	74
71	Evans KK, Fisher LL	2019	Australia	RCT	185	Group A	Group B	Effectiveness	Safety	79
72	Fisher MM, Green NN	2018	UK	Cohort	305	Group A	Group B	Effectiveness	Safety	64
73	Green OO, Hill PP	2020	USA	RCT	160	Group A	Group B	Effectiveness	Safety	86
74	Hill QQ, Irvine RR	2019	Canada	Observational	230	Group A	Group B	Effectiveness	Safety	76
75	Irvine SS, Jackson TT	2018	UK	RCT	150	Group A	Group B	Effectiveness	Safety	85
76	Jackson UU, King VV	2020	USA	Cohort	315	Group A	Group B	Effectiveness	Safety	68
77	King WW, Lamb XX	2019	UK	RCT	165	Group A	Group B	Effectiveness	Safety	83
78	Lamb YY, Martin ZZ	2018	USA	Observational	275	Group A	Group B	Effectiveness	Safety	72
79	Martin AA, Nash BB	2020	India	RCT	170	Group A	Group B	Effectiveness	Safety	87
80	Nash CC, Owen DD	2019	Australia	Cohort	295	Group A	Group B	Effectiveness	Safety	67
81	Owen EE, Patel FF	2018	UK	RCT	155	Group A	Group B	Effectiveness	Safety	84
82	Patel GG, Quinn HH	2020	USA	Observational	265	Group A	Group B	Effectiveness	Safety	74
83	Quinn II, Ryan JJ	2019	Canada	RCT	180	Group A	Group B	Effectiveness	Safety	80
84	Ryan KK, Scott LL	2018	UK	Cohort	300	Group A	Group B	Effectiveness	Safety	66
85	Scott MM, Taylor NN	2020	USA	RCT	160	Group A	Group B	Effectiveness	Safety	86
86	Taylor OO, White PP	2019	China	Observational	245	Group A	Group B	Effectiveness	Safety	73
87	White QQ, Young RR	2018	China	RCT	165	Group A	Group B	Effectiveness	Safety	83
88	Young SS, Zhang TT	2020	USA	Cohort	310	Group A	Group B	Effectiveness	Safety	69
89	Zhang UU, Zhou VV	2019	UK	RCT	155	Group A	Group B	Effectiveness	Safety	84
90	Zhou WW, Adams XX	2018	USA	Observational	270	Group A	Group B	Effectiveness	Safety	71
91	Adams YY, Baker ZZ	2020	Canada	RCT	135	Group A	Group B	Effectiveness	Safety	89
92	Baker AA, Carter BB	2019	UK	Cohort	290	Group A	Group B	Effectiveness	Safety	66
93	Carter CC, Clark DD	2018	USA	RCT	175	Group A	Group B	Effectiveness	Safety	81
94	Clark EE, Davis FF	2020	India	Observational	260	Group A	Group B	Effectiveness	Safety	74
95	Davis GG, Evans HH	2019	Australia	RCT	185	Group A	Group B	Effectiveness	Safety	79
96	Evans II, Fisher JJ	2018	UK	Cohort	305	Group A	Group B	Effectiveness	Safety	64
97	Fisher KK, Green LL	2020	USA	RCT	160	Group A	Group B	Effectiveness	Safety	86
98	Green MM, Hill NN	2019	Canada	Observational	230	Group A	Group B	Effectiveness	Safety	76
99	Hill OO, Irvine PP	2018	UK	RCT	150	Group A	Group B	Effectiveness	Safety	85
100	Irvine QQ, Jackson RR	2020	USA	Cohort	315	Group A	Group B	Effectiveness	Safety	68

